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Muscular dystrophies (MDs) are neuromuscular disorders characterised by chronic, 
usually progressive, skeletal muscle weakness. Individuals often lose walking ability and can 
suffer terminal cardiorespiratory complications. Determining the genetics of a disease helps 
provide diagnosis, prognosis, genetic counselling, and the basis for rational therapeutic 
design.  
A naturally occurring sheep model of autosomal recessive congenital MD was identified 
in WA in the 1950’s and preserved as a research colony. The pathological features and 
distribution of this MD is novel. A sheep model of MD is incredibly valuable; sheep have 
similar skeletal muscle mass to humans, representing a significant improvement over smaller 
mammals in which to trial therapies. Successfully characterising the causative gene(s) would 
enable a possible target for new therapies and may open new lines of investigation into better 
understanding and treatment of MD in humans. 
This project utilised a two-pronged approach to investigate the genetics of this ovine MD. 
First, bioinformatics analysis of SNP genotyping for multiple individuals in the flock by a 
50,000 SNP array in combination with the latest sheep genome reference build released by 
the International Sheep Genome Consortium, enabling homozygosity mapping, genetic 
linkage and association mapping. Second, molecular biological approaches further explored 
the identified prime candidate gene by cDNA sequencing.  
This research project identified ROCK2 as the prime candidate gene most likely 
harbouring a mutation causing the muscular dystrophy in this internationally unique ovine 
model. It also demonstrated for the first time in sheep the existence of ROCK2m, an isoform 
of ROCK2 preferentially expressed in skeletal muscle. This work has set the stage for further 
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Definitions & Abbreviations  
Allele Alternative DNA sequence at a locus 
 
Amino acid Individual components of a protein. Dictated by a 3 base codon of DNA. 
 
DNA Deoxyribonucleic acid 
 
Exon Segment of a gene which is translated to an end product. A given gene may have 
multiple exons 
 
Exon splicing Process by which the exons of a gene are joined together as a step 
towards the production of a mature RNA product. May have alternative forms in which 
exons are absent, introns preserved, or the inclusion of an alternative acceptor site 
changes the upstream or downstream exon 
 
Gene A section of DNA that gets transcribed into RNA and then into protein 
 
Genetic locus A particular point in the genome 
 
Genetic Polymorphism A DNA variant occurring at an incidence of less than 99% 
 
GWAS Genome-Wide Association Study 
 
Intron Segment of a gene which is not translated into a product. A given gene may 
have multiple introns.  
 
Map Distance/Unit usually expressed as either map unit (MU) or centimorgan (cM) is 
a measure of recombination frequency between two genetic loci. One cM represents the 
genetic distance between genes at which one product of meiosis in 100 will lead to a 
recombinant product (recombination frequency of 1%).  
 
Moore’s Law Observation that over the history of computing hardware the speed of 
processors approximately doubles every 2 years; with a concomitant drop in cost   
 
MyD Myotonic Dystrophy 
 
MD Muscular Dystrophy 
 
NM Nemaline myopathy 
 
NMD NeuroMuscular Disorders 
 
Nucleotide A single base of DNA. DNA is made up of four nucleotide bases;  




1. Introduction and Literature Review 
1.1. Overview 
This literature review gives an outline of genetics and disease, genomics and 
associated bioinformatics challenges, neuromuscular disorders, the ovine congenital 
progressive muscular dystrophy model, comparisons of the model with human disease 
and the field of bioinformatics. The section concludes with the research hypothesis and 
aims, and the significance of this project work. The following is a short overview of this 
honours project and its relevance. 
Muscular dystrophies (MDs) are neuromuscular disorders, genetic in nature, which 
present with chronic, usually progressive, weakness of skeletal muscle (used for 
voluntary movements). In affected individuals, MD negatively affects the performance 
of daily activities; in many cases leading to the loss of walking ability and 
complications resulting in early death. Congenital MDs (CMDs) are usually present 
from birth and represent life-long disease, with a high burden placed on affected 
individuals and caregivers. The selective targeting of muscle in MD is not yet well 
understood, but animal models can be utilised to explore disease pathology and 
progression, and to trial potential treatments of palliative or therapeutic nature. 
This project utilises bioinformatics tools and techniques to identify the cause of a 
naturally occurring MD in sheep, in the hope of this animal model being useful in the 
research of human disease. The similarities between sheep skeletal muscle mass and 
that of humans, in contrast to the differences between that of humans and the most 
popular current animal models, such as mice, will allow a much more effective 
translation of trial treatment modalities to medical intervention. The greater skeletal 
muscle mass of sheep also provides improved opportunity to examine affected tissue, 
important in developing pathophysiological understanding. 
Through use of genetic homozygosity mapping and association analysis, assisted by 
linkage analysis (all discussed later in this section) this project aims to identify genomic 
regions associated with development, or risk of development, of this disease. Through 
such analyses we hope to gain a greater understanding of not only this particular disease 
model, but of how MD selectively affects skeletal muscle tissue and of possible 
mechanisms of treatment. After identification of a prime gene candidate which was 
significant both statistically and biologically, this candidate was further explored using 
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molecular biological techniques to provide additional evidence for or against its 
involvement in the pathology. 
1.2. Genetics & Disease 
1.2.1. Importance of Genetics – could be removed or drastically reduced 
Our genome provides the template for our growth and cellular differentiation, 
dictating to a large extent the resistances and susceptibilities of our lifetime (Pierce, 
2010). This complete collection of our DNA; the instructions for building and 
maintaining ourselves as an organism, is organised into 23 pairs of homologous 
chromosomes in humans (Francomano and Kazazian, 1986). The inherited genome, 
through interaction with the environment, plays a major role in determining our ultimate 
fate (Hunter, 2005). Inheritance of a random recombination of our parents’ respective 
genomes through sexual reproduction results in the vast majority of our genes working 
correctly, but also of genetic variants with the potential to be disease-causing, or which 
are otherwise abnormal (Pierce, 2010, Tenesa and Haley, 2013). A functional unit of 
DNA is referred to as a gene and can be conceptualised as a single program written to 
create a specific protein product (Pierce, 2010). 
1.2.2. DNA to Protein 
Protein is the major structural and functional component of organisms (Pierce, 
2010). Functional protein in eukaryotes is generated from DNA by a multipart process, 
the overall sequence of events indicated graphically (Fig. 1.1.); first being transcribed 
into pre-mRNA and then processed, with the addition of a 5’ cap, poly-A tail, and exons 
spliced into mature mRNA (Clark, 2005).  
Alternate splicing (Fig. 1.2), can generate an alternative isoform of the product, 
which may have distinctly different biological activity than that of the more common 
isoform (Clark, 2005). The base sequences at the splice junctions are of major 





Figure 1.1. The central dogma of molecular biology. DNA is transcribed into RNA and then translated 
into protein. Figure from (Ianello Giassetti et al., 2013) 
human disease is the result of genetic mutations at these sites (López-Bigas et al., 2005, 
Crotti and Horowitz, 2009). Alternative splicing has been recently reported to take place 
in up to 94% of eukaryotic multi-exon genes, demonstrating that gene expression is not 
a simple instruction-to-product process and can be variable even in the case of a single 
gene, underscoring the importance of alternative splicing in understanding gene 
expression (reviewed by Chen et al., 2012). 
Subsequent to transcription, mature mRNA undergoes translation in the ribosome, 
first forming the ribosome-mRNA complex and being read by the ribosome as triplet 
codons, each triplet encoding an amino acid through the redundant genetic code. The 
correct amino acid is added to the sequence as transfer RNA is brought to complex and 
matches anticodon to codon for each triplet (Clark, 2005). The completed sequence of 
amino acids is referred to as a protein and, subsequent to the process of protein  
processing, this becomes a functional unit within the organism (Becker et al., 2008). 
This protein may be an enzyme, structural component or hormone and has a biological 




Figure 1.2. Exon splicing. Introns are removed from the pre-mRNA and exons joined. Alternative splicing 
can generate different isoforms through multiple mechanisms. (Figure from Sparknotes, 2013) 
 
 
Figure 1.3. Meiosis in diploid organisms. (Figure adapted from Marston and Amon, 2004) 
The human genome is diploid; each chromosome paired to its homologous partner 
and inherited one from each parent (Becker et al., 2008). For each gene there are two 
copies, or alleles, the DNA sequence of which may differ between copies (Clark, 2005). 
The generation of haploid DNA through meiosis (Fig. 1.3), in which only one copy of 
each chromosomal pair is present, is the basis by which sexual recombination of 
parental DNA takes place (Pierce, 2010). This haploid cell is referred to as a gamete, 
and the combination of both a maternal and paternal gamete results in the genome of a 
new diploid offspring (Pierce, 2010).  
The generation of haploid DNA for the purpose of reproduction is prone to error 
through both the copying of DNA by DNA polymerase, which has an error rate of 
approximately 1 in every 100 000 nucleotides, but also of errors related to 
recombination processes (Tempest, 2011). While there are mechanisms in place to 
recognize and correct these, they are not infallible and spontaneous genetic changes can 
result in deleterious traits in offspring (Tempest, 2011). Where these negative mutations 
are passed on to offspring we observe the generation of a new heritable disease trait. 
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1.2.3. Genetic Disease 
To some extent, all disease is genetic in nature, whether the breakdown of basic 
biological functions or the interplay of a host genome with a pathogen. Disease 
represents non-functional or aberrant behaviour of specific functions or tissues within 
an organism (Becker et al., 2008). Though all disease can be said to at least to have a 
genetic component, not all genetic mutations lead to disease (Pierce, 2010). Where 
protein production or gene function is unaffected by a mutation in a non-coding, non-
regulatory region, or a synonymous region undergoes mutation but the resulting amino 
acid does not change, the mutation is referred to as ‘silent’, though there is evidence that 
even translationally silent mutations can result in biological change (Cartegni et al., 
2002, Mullard, 2007,  Pierce, 2010).  
At other times, a mutation may occur in such a genomic region as to have 
detrimental effects on the organism; this may include disruption of protein formation, 
aberrant regulation of genetic expression, changes to exon splicing, or a host of other 
possibilities (Pierce, 2010). These effects can range from the relatively benign, to life-
long disease, to spontaneous termination of an affected fetus (Zatkova et al., 2004, 
Pierce, 2010).  
Mutations may be a change to a single base, or they may affect large sequences of 
DNA (Pierce, 2010). A point mutation affects only one base, while a frameshift 
mutation can change the reading frame of gene (Pierce, 2010). An insertion or deletion, 
for instance, changes the resulting amino acid for all subsequent triplet codons (Pierce, 
2010). DNA copy number variants (CNVs) in which a simple sequence spanning at 
least 1000 bases is of variable length between individuals is a contributor to disease, 
having been associated with a number in recent years; such as Alzheimer’s disease, 
Crohn’s disease and myotonic dystrophy (Rovelet-Lecrux et al., 2006, Fellermann et al., 
2006, Ashizawa and Sarkar, 2011). Gross changes to the genome through mutation may 
result in large-scale deletions of chromosomal segments, leading to loss of function 
from affected genes and downstream effects (Pierce, 2010). 
Genetic mutations can be caused by a wide range of factors; copy error, chemical 
mutagens, retroviral infections, or gene duplications and deletions resulting from the 
errors in recombination of haploid DNA during sexual reproduction are all possible 
mechanisms (Becker et al., 2008, Pierce, 2010). These accumulated errors become 
heritable and for any given lineage these potentially deleterious changes may lead to 
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disease. Congenital diseases are those that are present from birth, and generally genetic 
in nature (meaning that they are heritable) but they do not necessarily arise from an 
inherited disorder (Laing, 2012). 
1.2.4. Heritable Disease 
Heritable disease can be the result of mutations or dysregulation in which are 
monogenic, such as cystic fibrosis, which are referred to as Mendelian disorders. It can 
also be the result of complex polygenic disorders involving many genetic loci and 
environmental interactions, such as in multiple sclerosis (Kerem et al., 1990, The 
International Multiple Sclerosis Genetics Consortium, 2010, Tenesa and Haley, 2013). 
A simple disease gene variant in the diploid human genome may have dominant 
expression, in which a single inherited allele of the defective gene is enough to manifest 
the disease phenotype. Expression of recessive disease requires the inheritance of two 
defective alleles in order for the disease to manifest (Tenesa and Haley, 2013). In many 
cases, the interaction of the genome with environmental factors also plays a role in 
determining disease manifestation and/or severity (Tenesa and Haley, 2013). 
1.2.5. Disease & Treatment Investigation 
Traditionally, the development of understanding related to disease processes, and of 
treatment modalities, is a multipart process involving diverse areas of the biological 
sciences and expert collaboration from a range of sub-disciplines. 
The first step in understanding disease is the application of basic biological science 
principles; how do the presented symptoms suggest disease? Following this, the next 
step is often to undertake an in vitro investigation, in which the disease process or 
potential drug treatment is examined in cell culture (Ong et al., 2013). Recent years 
have seen the in silico modelling of disease and treatment to be an effective method for 
supplementing these findings prior to taking the research to its next step; subsequently, 
the disease is examined in a living biological system (Ong et al., 2013). This in vivo 
investigation is generally the most informative means of exploring disease pathogenesis 
and the safety of potential treatments prior to clinical trials, and it is for this reason that 
animal models represent a highly valuable tool in disease investigation (Allamand and 




1.2.6. Animal Models of Human Disease 
 
Animal models are used to study disease causes, patterns and treatments by 
examination of animals with a disease state mimicking that of human disease; this may 
be naturally occurring or the result of biological manipulation (Washington et al., 2009, 
Ng et al., 2012, Prather et al., 2013). For these models to be informative it is important 
to characterise the genotype and involved biological pathways in order to allow ease of 
investigation, the communication of findings, the generation of new affected individuals 
for study, and to provide the ability to extrapolate any findings into the understanding of 
human disease processes, management and treatment (Thyagarajan et al., 2003, 
Washington et al., 2009, van der Worp et al., 2010, Prather et al., 2013). The 
conclusions drawn from animal models will invariably contain inconsistencies as 
compared to humans but this form of biological interrogation allows a far more 
complete investigation than in vitro approaches and in a much more ethically 
permissive environment than in humans (van der Worp et al., 2010). The use of in silico 
models to study disease patterns and possible drug treatments provides a useful synergy, 
allowing development of further understanding without the death of animals 
(Ranganatha, 2012). 
1.3. Genomics & Bioinformatics Challenges   
1.3.1.  Genomics 
Genomics as a field has been developing at an exponential pace over the last two 
decades, brought about by rapid increases in technological power and computing 
complexity, in combination with advances in gene sequencing methodology and 
technologies (Magi et al., 2010, Alkan et al., 2011). It is the investigation, annotation 
and characterisation of the genetic code, providing us with the ability to intelligently 
interrogate the code of life in order to better understand its processes (Hawkins et al., 
2010). 
The beginnings of genomics owes not a small debt to the passage of legislation 
allowing research into the effects of ionising radiation on biological molecules and the 
creation of radioisotopes (U.S. Congress, 1974). These developments opened the door 
for Sanger sequencing of molecules and, in combination with the goals of the human 
genome project for reducing the costs of sequencing and development of automated 
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sequencing technologies, enabled large-scale investigations of life’s basic code (U.S. 
Department of Energy, 1990). 
The story of the development of high-throughput genomics is really the story of the 
Human Genome Project. This has been the fundamental driver of associated 
technologies and a lightning rod for vast amounts of funding poured into the field 
(Collins et al., 2003). While the human genome initiative was announced in 1986, the 
15-year project formally began in 1990. Over the next 11 years rapidly advancing 
technological and theoretical developments such as the use of polymerase chain reaction 
(PCR), bacterial artificial chromosomes (BACs), shotgun sequencing and the 
development of oligonucleotide microarrays led to the confirmation of the existence of a 
third form of life (the Archaea), the publishing of complete DNA sequences of multiple 
smaller genomes, the publication of the initial working draft of the full human genome 
sequence in 2000 and 99% of the euchromatic genome completed by 2004 (the 50th 
anniversary of Watson & Crick’s discovery of the structure of DNA itself)  (Woese and 
Fox, 1977, Venter et al., 2001, Human Genome Consortium, , 2004). 
The development of PCR allowed the amplification of DNA samples to the point 
they could be analysed more readily; by amplifying target sequences we could then 
examine specific genomic regions of interest (Bartlett and Stirling, 2003). These 
provided the first real mechanism of genomic investigation for evidence of genetic 
linkage to disease, especially in notable family studies localising complex disorders 
such as autoimmune disease (Altmüller et al., 2001). 
The development of bacterial artificial chromosomes represented a key advance in 
genomics; they are propagated in Escherichia coli, which are able to carry large (~150 
kbp) inserts stably (Venter et al., 1998). These BACs can then each be individually 
sequenced. This technique can be used to target specific regions of DNA or randomly, 
and the resulting sequences placed into a developed genomic map.  
The process of breaking up the DNA molecule into smaller fragments and 
sequencing them concurrently is referred to as ‘shotgun sequencing’ and the basic 
approach was first developed shortly after that of Sanger sequencing itself (Sanger et 
al., 1982). The present-day approach uses computational analysis to reassemble the 
resulting fragments into coherent sequences referred to as ‘contigs’ (contiguous 
segments) and utilises paired end reads to build ‘scaffolds’ over larger sections in order 
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to mitigate the difficulties in placing these correctly, especially where DNA sequences 
are highly repetitive such as in CNVs (Waterston et al., 2002). This approach may be 
used in two major ways; the first is hierarchical shotgun assembly, in which the genome 
is broken up into an overlapping collection of intermediate clones like bacterial artificial 
chromosomes, the sequence of the individual intermediates then analysed and the BAC 
sequences merged back together (Waterston et al., 2002). The second approach is 
whole-genome shotgun assembly, in which the entire genome is fragmented and 
sequenced concurrently, though there is greater risk in reorganising these fragments 
without the framework or a BAC library, paired-end sequencing largely overcomes this 
drawback (reviewed by Shendure and Ji, 2008). At the time the human genome project 
was concluding, it was suggested that the most effective approach would be to use 
whole-genome shotgun sequencing and fill in remaining gaps through targeted 
sequencing using BACs (Venter et al., 1998). 
The development of oligonucleotide microarrays allowed the identification of 
genomic variation, especially single nucleotide polymorphisms and copy number 
variation, far more cost effectively and easily than DNA sequencing (Maskos and 
Southern, 1992, Sebat et al., 2004). As genetic markers, copy number variations are 
easily identified, highly polymorphic and can be mapped throughout the genome (Sebat 
et al., 2004, Levy et al., 2007). Microarrays have been adopted throughout the 
biological sciences, being used for disease gene discovery, expression profiling and 
across multiple species (Meltzer, 2001, Conway and K, 2003, Vallee et al., 2006). 
 
Figure 1.4. Change in DNA sequencing costs over time. (Figures from Wetterstrand, 2013) 
The years since the project’s formal conclusion have only seen a more rapid 
increase in the speed and economy of DNA sequencing and genomics, accelerating even 
faster than Moore’s law would have predicted (Fig. 1.4). While formally concluded, the 
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project is ongoing; the scientific community continues to explore the specific functions 
of genes and their variants, the true complexity of the human genome remains to be 
understood (Frazer, 2012). 
The genomes of many organisms have been well characterised over recent years; the 
human mitochondrial genome (16.6 kb) sequenced in 1981, the first eukaryotic 
chromosome (chr 3 of Saccharomyces cerevisiae, 315 kb) sequenced in 1992, the first 
free-living organism (Haemophilus influenza, 1.8 Mb) sequenced in 1995, the first 
complete eukaryotic genome sequenced in 1996 (S. cerevisiae, 12.1 Mb), and the 
human genome being completed in 2006 (3.2 Gb) (Anderson et al., 1981, Oliver et al., 
1992, Fleischmann et al., 1995, Goffeau et al., 1996, Dhand, 2006). As of June, 2013 
the complete genome of 3299 viruses, 2497 archaea and bacteria, and 190 eukaryotes 
are available to the research community (Kanehisa and Goto, 2000, Kanehisa et al., 
2012, EMBL-EBI, 2013). 
1.3.2.  Traditional and Second-Generation DNA Sequencing 
The science of sequencing genomes has changed a great deal over the years; from 
the development of Sanger sequencing in 1977 the field has grown by leaps and bounds 
along with computing power and more advanced technologies (Sanger et al., 1977, 
Hawkins et al., 2010). Next Generation Sequencing (NGS) (otherwise referred to as 
Second-Generation Sequencing) such as Illumina GAII and Roche454 are much more 
cost effective and speedy than the first generation technologies, and now Third 
Generation Sequencing (TGS) technologies are in development, with the aim of further 
reducing costs and increasing the accuracy of genotyping (Check Hayden, 2009, Schadt 
et al., 2010).  
1.3.3.  Bioinformatics Challenges for NGS  
Sequencing using next-generation technologies has dropped dramatically in price, 
but the analysis of the results remains a difficult challenge; while advancements in the 
field are leading to the $1000 sequenced genome, the analysis represents a process that 
is lengthy by comparison and with costs that are considerably greater, and often hard to 
estimate (Service, 2006, Sboner et al., 2011). Many aspects of the data processing, tools 
investigation and use, problem solving and optimization, in addition to the human hours 
(Sboner et al., 2011) required are difficult to quantify, giving rise to the adage ‘it’s the 
era of the $1000 genome, but the $100,000 analysis’ (Mardis, 2010). The inability to 
automate much of the work represents a major bottleneck and, while sequencing costs 
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may have dropped more quickly than Moore’s law, storage capacity has only kept pace, 
meaning that this, too, represents a bottleneck for effective use of NGS for genomic 
discovery (Sboner et al., 2011).  
NGS technologies have a wide range of applications; used for variant discovery by 
resequencing target regions of interest or whole genomes, de novo assemblies, 
transcriptome analysis using RNA-sequencing (RNA-seq), genome-wide profiling of 
epigenetic markers, and species classification with gene discovery in metagenomics 
studies (reviewed by Metzker, 2010). To gain an informative result from a mass of NGS 
reads is computationally intensive and requires a multistep pipeline (Nielsen et al., 
2011, Dolled-Filhart et al., 2013).  
The process of mapping millions of short reads to the billions of possible positions 
within the genome is not a computationally trivial step; specialised software must 
consider the likely start point for each read and account for variation in base call quality 
(Horner et al., 2010). This is achieved by use of alignment algorithms that have been 
designed to deal with specialised input, meaning that the parameters of this are subject 
to stringent criteria. The length of reads, platform of generation, whether the reads are 
single- or paired-end, whether the resulting alignment can have gaps and the number of 
individual reads all factor in to what is the most appropriately designed algorithm for 
alignment of the reads to the reference genome (Horner et al., 2010).  Many algorithms 
focus on speed of alignment over quality, while some take significantly longer in the 
pursuit of quality, and still others try to blend the two approaches. There is no ‘gold 
standard’ alignment algorithm, and the field is rapidly shifting as unserviced niches are 
discovered and tools written to fill them (Horner et al., 2010).  
In most cases, the tools developed to meet these niches are written for use in the 
Linux/UNIX environments, meaning that implementation involves adept manipulation 
of the command line and preferably a familiarity with scripting and programming 
(Stajich and Lapp, 2006). The quickly changing nature of tools and platforms means 
that there is rarely time for individual tools to mature to the point that they are ported to 
additional platforms or have all outstanding issues with compatibility and use resolved 
(Gonzalez-Galarza et al., 2012). Much of the work is developed through the open-
source paradigm, meaning that these tools are free and the source code available for 
modification, but there are inconsistent levels of support and documentation, and the 
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output of a specific software tool may at times require considerable expertise to parse 
(Stajich and Lapp, 2006, Kumar and Dudley, 2007). 
In DNA sequencing (DNA-seq) using NGS technologies, it is subsequent to the 
alignment of reads to the corresponding reference genome that variant calling is 
undertaken (Horner et al., 2010). The major computational challenge at this step is to 
distinguish ‘true’ variants from errors in alignment or in base-calling by the sequencer 
platform, and generally requires a database of known polymorphisms in order to gain 
good results (Nielsen et al., 2011). Despite the inherent challenges, this step is of major 
importance to successfully identifying potential disease-causing or risk-generating 
variants (Dolled-Filhart et al., 2013). This is complicated by insertions or deletions 
(indels), which are especially problematic in the case of alignments performed by 
algorithms that disallow gaps, where there are significant PCR artefacts or variable GC 
content in short reads (in the case of single-end sequencing) and variable quality scores 
between bases; these generally degrading towards the end of individual reads (Nielsen 
et al., 2011, Dolled-Filhart et al., 2013). 
The results of alignment and variant calling are thousands of differences between 
the reference genome and that under investigation (Nielsen et al., 2011). At this stage, 
these are filtered based on known variants in the population, and the results investigated 
for biological plausibility in leading to the potential disease pathology under 




Figure 1.5. RNA-sequence analysis pipeline. (Figure from Mutz et al., 2013). 
The use of NGS for generating a snapshot of the transcriptome is a valuable tool to 
facilitate gene annotation and identification of splicing variants; possessing greater 
sensitivity than microarrays and having increased facility over real-time PCR with 
lower costs (Mutz et al., 2013). As with DNA-seq, the process of RNA-seq 
investigation (Fig. 1.5) depends upon a well annotated reference transcriptome to 
underpin the analysis (Mutz et al., 2013). 
1.3.4. Single Nucleotide Polymorphisms 
Comparison of DNA sequences between individuals can reveal positions at which a 
specific, single base residue is variable (reviewed by LaFramboise, 2009). These single 
nucleotide polymorphisms (SNPs) are highly abundant, occurring approximately 1 in 
every 1000 bases of the human genome (Syvanen, 2001). Where these changes occur in 
a biologically active genetic region (e.g. coding regions of genes which generate a 
functional or structural protein) they can be sufficient to cause monogenic disorders, 
such as cystic fibrosis, Limb Girdle Muscular Dystrophy Type 2L (LGMD2L) or 
Duchenne Muscular Dystrophy (DMD) through interruption of normal gene expression 
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(Den Dunnen et al., 1989, Kerem et al., 1990, Hicks et al., 2011). This may act to 
directly cause disease, or may result in the increased risk of disease development, based 
on additional genetic and environmental factors.  
In recent years, SNPs have been utilised to assist in identification of causative 
disease genes and to narrow genetic regions of interest, for which they are ideally suited 
due to their frequency and relatively uniform distribution throughout the mammalian 
genome (Sellick et al., 2004, Hardy and Singleton, 2009). They are well suited to be 
used as proxies for specific genomic regions due to the ‘linkage’ of nearby genomic 
regions to one another; especially those which have been validated as highly predictive 
of local genomic regions and are strongly conserved in a population (referred to as ‘tag’ 
SNPs) (The International HapMap Consortium, 2005, LaFramboise, 2009).  
Analyses using SNPs represent both reduced cost and increased adaptability over 
microsatellite marker analysis (Sellick et al., 2004, Halperin et al., 2005, Zhang et al., 
2005, Nielsen et al., 2011). 
 
Figure 1.6. Haplotype as unit of statistical testing. Disease can be associated with a particular haplotype.  
(Figure from Chao, 2012). 
Over a particular genomic region, the particular combination of alleles at these 
single nucleotide polymorphic sites is referred to as the haplotype (LaFramboise, 2009). 
For a given haplotype there may be an associated risk of disease or protective 
mechanism (Fig. 1.6), which may result not just from the influence of a particular SNP 
allele, but of the combination and potential interaction of multiple polymorphic 
nucleotides (LaFramboise, 2009). 
The use of SNPs is now commonplace in human genomics, and the widespread 
adoption of SNPs as targets in genomic analysis has led to the development of genome-
wide SNP arrays for several species (Fan et al., 2010). These have succeeded in 
identifying genetic polymorphisms either causative or risk-associated for a range of 
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human diseases, such as bipolar disorder, Crohn’s disease and diabetes (Wellcome Trust 
Case Control Consortium, 2007). 
1.3.5. Linkage 
As an integral part of positional cloning, linkage analysis is the basis of identifying 
diseases which exhibit Mendelian inheritance patterns, in which a single mutation 
causing disease is propagated generationally (Botstein and Risch, 2003). Positional 
cloning identifies specific chromosomal regions which are transmitted within families, 
along with a disease phenotype of interest, thus demonstrating genetic linkage of a 
region with the goal of identification of the disease-causing mutation (Altmüller et al., 
2001). It is thus a family-based approach limited to Mendelian disorders, in contrast 
with association analysis (further explained later) which does not require a defined 
pedigree and which can be applied to complex diseases (Altmüller et al., 2001).  
It has been used to successfully identify the causative loci in a range of monogenic 
diseases, leading to potential diagnostics, treatments and possible cures, the most well-
known of which being cystic fibrosis and Huntington’s disease (Kerem et al., 1989, Di 
Maio et al., 1992) 
Linkage is a measure of how connected individual loci are in the genome, based on 
their physical proximity (Cui et al., 2010). Those regions between which a 
recombination event is unlikely to occur can be considered to be 'linked' in that a given 
genetic feature will co-segregate with nearby genetic features during meiotic 
segregation (Cui et al., 2010). Thus we can use linked genetic markers like SNPs to 
predict the presence of a local genotype with a high degree of confidence (Sellick et al., 
2004, Zhang et al., 2005). The measure of linkage is usually indicated by Log Of the 
Odds (LOD) scores, with greater than 3.0 being considered reasonable evidence for 
linkage, representing a 1000 to 1 chance of such a such a statistical result was arrived 
upon by chance alone (Teufel et al., 2006, Fukuda et al., 2009, Cui et al., 2010). 
As a means to investigate genotypic variation underlying phenotypic variation 
linkage analysis is limited by several concerns; where misdiagnoses, heterogeneity, or 




1.3.6. Linkage Disequilibrium and Genetic Association Analysis 
Linkage Disequilibrium (LD) is a statistical construct measuring the correlation of 
alleles at different loci (Visscher et al., 2012). It does not assume a necessary physical 
proximity, though in general loci that are closer together will possess higher LD; two 
genetic features separated by a large map distance may nevertheless possess tight 
correlation, meaning that the presence of a specific genotype in one region can be 
predictive of a corresponding genotype in another (Devlin and Risch, 1995, Cui et al., 
2010). LD between loci is strengthened through the evolutionary forces of mutation, 
drift and selection and is weakened by recombination events (Hartl and Clark, 1997). 
The larger the effective population size, the weaker will be the LD for a given map 
distance (Hill and Robertson, 1968). 
Genetic association testing examines the association of a genetic variant (e.g. SNP 
allele, microsatellite, or haplotype) with some phenotypic condition by statistical 
analysis, thus potentially providing new insights into related pathological pathways 
(Visscher et al., 2012). Where this correlation is able to be understood to be biologically 
relevant, it may lead to a greater understanding of disease pathology and the causative 
effects of the variant.  
1.4. Neuromuscular Disorders 
Neuromuscular disorders (NMD) are defined by involvement of both the peripheral 
nervous system and the muscles and they affect all age groups; from fetuses to the 
elderly (Emery, 1991, Laing, 2012). A 1991 worldwide review estimated that their 
prevalence amongst both sexes was approximately 1 in 3500 people (Emery, 1991).  
They are generally inherited and characterised by chronic, often progressive, loss of 
skeletal muscle strength leading to a loss of function, and are life-long diseases (Tews, 
2002, Mercuri et al., 2007, Laing, 2012). In advanced cases, respiratory and cardiac 
failure ensues, resulting in early death (Rochester and Esau, 1994, Gozal, 2000, 
McDonald, 2002). For most neuromuscular disorders the treatment options are 
extremely limited and reduced to mitigation of symptoms rather than curative 
interventions. These include walking/standing frames, feeding tubes and adaptive 
technologies to help affected individuals carry out daily tasks, drug treatments and 
surgeries to lessen the worst of the resulting symptoms and usually require the attention 
of referred specialists (Muscular Dystrophy Association, 2013). In the case of 
autoimmune disorders drugs treatments can slow or halt the pathology, and prednisone 
21 
 
is currently prescribed for individuals with Duchenne’s muscular dystrophy and some 
other conditions to slow muscle breakdown (Weiner, 2004, Beenakker et al., 2005, 
Muscular Dystrophy Association, 2013).  
The term “NMD” encapsulates a wide range of conditions and involves a large 
variety of biological pathways; as of January 2013 more than 300 different genes have 
been shown to be causative of one or more of these conditions 
(http://www.musclegenetable.fr). This includes those in which the nerves and 
neuromuscular junctions are affected, such as in multiple sclerosis, those having 
neurological involvement such as in Parkinson’s disease, or those that directly affect the 
skeletal muscle, such as in a range of Muscular Dystrophies (MDs) (Campbell, 1995, 
Emery, 2002, Lutton et al., 2003, Bertini et al., 2011, Pedrosa and Timmermann, 2013). 
The MDs can result in impaired cognition and neurological development, pathological 
cardiac involvement, hearing loss, eye malformation or degradation, loss of respiratory 
function, and central nervous system pathology (Dubowitz, 1965, Zellweger, 1965, 
Cohen et al., 1968, Kondo-lida et al., 1999, Gozal, 2000).  
1.4.1.  Muscular Dystrophy 
MD normally presents with selective defects of the skeletal muscle proteins, along 
with muscle cell and tissue death (Emery, 2002). It is usually progressive, and muscular 
dystrophy is estimated to affect 1 in 3500 people (Emery, 1991). MDs are genetic in 
nature (over 30 different genes having been identified as causative) but are not always 
inherited; it is estimated that approximately one third of MDs are the result of a de novo 
mutation (Laing, 2012). The cost of these debilitating disorders in Australia is estimated 
to be approximately $1.5 billion per year, with a case burden three times greater than 
that of multiple sclerosis and ten times greater than diabetes; the disability adjusted life 
years per case is greater for these conditions than for any of National Health Priority 
Area (Access Economics, 2007). 
1.4.2.  Congenital Muscular Dystrophy 
Congenital muscular dystrophies are a group of MDs that are usually present at birth 
and are genetic in nature, being therefore heritable (Bertini et al., 2011).  
Following is a discussion of four MDs of special relevance to this project. 
1.4.3.  Duchenne Muscular Dystrophy 
22 
 
Duchenne Muscular Dystrophy (DMD) is a heritable disease caused by mutations in 
the X-linked dystrophin gene (DMD); this being the largest gene in the human genome 
(Kwiatkowska and Slomski, 1992, Blake et al., 2002). The disease has the second 
highest incidence of all inherited pathologies, affecting one in 3300 live male births 
(Emery, 1991). One in 10 000 haploid genomes will develop such a mutation de novo, 
meaning that genetic screening will never entirely eliminate the incidence of the 
disease; one third of all new cases are the result of such mutations (Barbujani et al., 
1990). The lack of dystrophin protein leads to a breakdown of the necessary anchoring 
of sarcolemma protein to the underlying cytoskeleton in skeletal muscle, which results 
in increased damage to muscle cells and their breakdown (Fig. 1.7) with involved 
intellectual impairment (Zellweger, 1965, Karagan, 1979, Leibowitz and Dubowitz, 
1981, Bresolin et al., 1994). This condition becomes noticeable from ~5 years of age 
and leads to a progressive loss of motor function, the majority of patients becoming 
wheelchair bound by the age of 12 and developing terminal cardiorespiratory 
complications by their second decade (Nowak and Davies, 2004). 
 
Figure 1.7. Histology of healthy and dystrophic muscle in Duchenne muscular dystrophy. Characteristic 
dystrophic muscle features are the result of successive rounds of degeneration and regeneration; including 
central nuclei, variation in fiber size and build-up of connective tissue between muscle fibres. Brown staining 
dystrophin is noticeably absent in dystrophic muscle tissue. (Figure adapted from Davies and Nowak, 2006). 
1.4.4.  Myotonic Dystrophy 
Together types I and II myotonic dystrophy (MyD) affect one in 8000 people 
(Longman, 2006). The disease follows an autosomal dominant inheritance pattern and is 
a slowly progressive, multi-system disorder (Longman, 2006). It affects not only 
skeletal muscle but also cardiac and smooth muscle, the eyes, the endocrine and the 




Figure 1.8. Genetics and pathology of myotonic dystrophy types I & II. (Figure from Turner and Hilton-Jones, 
2010). 
There is associated neurological pathology and cardiorespiratory complication 
(Turner and Hilton-Jones, 2010). The condition is the result of expanded repeats in 
either DMPK (type I) or ZNF9 (type II) and severity is correlated with the size of the 
expanded repeat sequence (Fig. 1.8) (Brook et al., 1992, Klesert et al., 1997, Turner and 
Hilton-Jones, 2010, Ashizawa and Sarkar, 2011, Morales et al., 2012).    
1.4.5.  Nemaline Myopathy 
The congenital myopathies like Nemaline Myopathy (NM) are defined based on 
structural abnormalities of the muscle fibres (North et al., 1997). NM can be inherited 
through either an autosomal dominant or recessive model and shows heterogeneity, with 
several causative mutations identified in genes generating components of the sarcomeric 
thin filaments, and, recently, in KLH40, the exact function of which is not yet known 
(Ilkovski et al., 2001, Ravenscroft et al., 2013). It presents with selective muscle 







Figure 1.9. (left) Child affected with nemaline myopathy.  
Figure 1.10. (right) Gomori trichrome staining in nemaline myopathy. Nemaline bodies indicated. (Adapted 
from Ilkovski et al., 2001). 
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1.4.6. Limb Girdle Muscular Dystrophy Type 2  
Limb girdle MD (LGMD) is a heterogeneous collection of nearly 20 different 
diseases involving mutations at more than 50 genetic loci; depending on the subtype it 
has been shown to follow autosomal dominant (type 1) or autosomal recessive (type 2) 
inheritance (Nigro, 2003, Zatz et al., 2003). The disorder is rare; the incidence in the 
wider population for all LGMDs together being estimated at approximately 4-6 per 100 
000 (van der Kooi et al., 1996, Urtasun et al., 1998). 
 
 
Figure 1.11. Proteins involved in pathogenesis of limb girdle muscular dystrophy. (Figure from Zatz et al., 
2003). 
Individuals with LGMD generally show muscle weakness and wasting restricted to 
the limb musculature (proximal greater than distal) and muscle 
degeneration/regeneration evident from tissue biopsy (Laval and Bushby, 2004). The 
molecular mechanisms involved in some subtypes are indicated (Fig. 1.11). Type 2G 
has been reported to be associated with nemaline bodies in affected skeletal muscle 
tissue (Paim et al., 2013). Onset, progression, weakness and wasting are highly variable 
between individuals and genetic subtypes (Laval and Bushby, 2004).  
Limb Girdle Muscular Dystrophy type 2 (LGMD2) has been linked to mutations in 
15 known genes (Table 1.1) and, depending on the subtype, symptoms show marked 
intrafamilial and interfamilial variability (van der Kooi et al., 1996). Possible treatments 
under investigation include exon skipping through gene therapy and cortisone therapy 




Table 1.1. Subtypes of limb girdle muscular dystrophy type 2, with associated genomic positions, affected 
genes and associated proteins (Adapted from Laval and Bushby, 2004) 
LGMD2 Type Chromosome Gene Protein 
A 15q15.1-q21.1 CAPN3 calpain-3 
B 2p13.3-p13.1 DYSF dysferlin 
C 13q12 SGCG gamma-sarcoglycan 
D 17q12-q21.3 SGCA alpha-sarcoglycan 
E 4q12 SGCB beta-sarcoglycan 
F 5q33 SGCD delta-sarcoglycan 
G 17q12 TCAP telethonin 
H 9q31-q34.1 TRIM32 tripartite motif protein (TMP-32) 
I 19q13.3 FKRP fukutin-related protein 
J 2q24.3 TTN titin 
K 9q34.1 POMT1 protein O-mannosyltransferase 
L 9q31 FKTN fukutin 
M 1p34-p33 POMGNT1 protein O-linked-mannose beta-1,2-N-
acetylglucosaminyltransferase 1 
N 14q24.3 PMT2 protein O-mannosyltransferase 2 
1.5. A Sheep Model of Muscular Dystrophy 
1.5.1.  The OCPMD Flock 
A naturally occurring animal model of a congenital muscular dystrophy was 
discovered in south-western Australia in the 1950’s (McGavin and Baynes, 1969) and 
has been preserved as a research colony in the intervening years; bred and pedigree 
tracked by researchers and staff at both Murdoch University and the University of 
Western Australia. The Ovine Congenital Progressive Muscular Dystrophy (OCPMD) 
flock provides a singular opportunity to investigate this new disease.  
1.5.2.  Inheritance 
This disease follows an autosomal homozygous recessive inheritance pattern and the 
specific phenotype has not been reported to manifest in any example other than this 
pedigree (Richards et al., 1988a; personal communication with Prof. Nigel Laing). 
Affected sheep have been identified over four Australian states; initially in Queensland, 
and subsequently in Western Australia, New South Wales and Victoria (Dent et al., 
1979, Richards et al., 1988b).  
1.5.3.  Disease Morphology 
Characterised by abnormal myofiber morphology, progressive myofiber loss and 
adipose replacement (Fig. 1.12), affected animals present with congenital muscle 
weakness, and selective skeletal muscle tissue degrades over time (Richards et al., 1986, 
Richards et al., 1988a). The progressive fibrous and fatty tissue replacement in the 
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muscle fibers of the hip, stifle and hock results in an inability to effectively mobilise the 
hindquarter muscles, locking these joints in extension, leading to a stiffened gait 
(Richards et al., 1986). The disease preferentially affects type I muscle fibers, sharing 
this feature in common with myotonic dystrophy and certain congenital myopathies of 
humans (Richards et al., 1988a, North et al., 1997, Longman, 2006). Type I fibers are 
those which are ‘slow-twitch’; they provide endurance and fatigue slowly, while type II 
fibers are ‘fast-twitch’; function in short bursts of action and fatigue quickly 
(Cunningham, 2007). The affected fibers are proportionately higher in those muscles 
which affect posture, meaning that this is particularly affected in the pathology 
(Richards et al., 1986, Richards et al., 1988a).  
 
Figure 1.12. Adipose replacement in OCPMD-affected skeletal muscle tissue of the anconaeus of a 2 year old 
ewe from the ovine congenital muscular dystrophy flock, with the remaining fibers being severely dystrophic. 




Figure 1.13. Most severely affected muscles in OCPMD-affected sheep. Labeled muscles as follows:  (1) 
Flexors of shoulder (2) Flexors of carpus (3) Flexors of digits (4) Digits (5) Extensors of hip (6) Extensors of 
stifle (7) Extensors of hock (8) Flexors of digits (9) Digits (10) Triceps brachii (11) Vastus intermedius (12) 





Figure 1.14. Transverse section of vastus intermedius from a 14-week old dystrophic ram showing the broad 
range of muscle fibers, rounded profiles, internal nuclei and peripheral sarcoplasmic masses typical of 
dystrophic tissue (Richards et al., 1988a). 
The primary muscles affected include the extensors of the hip, stifle and hock joints, 
flexors and digits of the hind limb, the extensors of the elbow, flexors of the shoulder, 
carpus and digits of the fore limb (Richards et al., 1988a). Severe and consistent 
affection has been reported in a number of muscles (Fig. 1.13) (Richards et al., 1988a). 
The lesions described are consistent with the inherited muscular dystrophies, with 
dystrophic fibers usually distributed throughout the affected muscles, however being 
occasionally seen grouped into a focal loss of myofibrils, resulting in irregular 
sarcoplasmic masses (Fig. 1.14) (Richards et al., 1988a, North et al., 1997).  
 
Figure 1.15. Disorganised fibrillar material containing small nemaline bodies beneath the cell membrane of 
dystrophic fiber (Richards and Passmore, 1989). 
 
Figure 1.16. Longitudinal section of the vastus intermedius in an OCPMD affected sheep. Severe atrophy of 
fibers results in chains and clusters of small, dark-staining nuclei. (Richards et al., 1988a). 
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Respiratory infections stemming from decreased mucocilliary clearance and ruminal 
tympany as a result of affected skeletal muscle tissue in the diaphragm have also been 
observed (Richards et al., 1986). 
Similar to NM, nemaline bodies are present in affected tissues (Fig. 1.15) (North et 
al., 1997). In otherwise intact muscle fibers, there are long rows of centrally placed 
muscle nuclei (Fig. 1.16) as in myotonic dystrophy (McGavin and Baynes, 1969). 
There is significant variation in the severity and rate of progression between affected 
individuals (Richards et al., 1986). 
1.5.4.  Diagnosis 
Other than muscle pathology and muscle weakness, markers for disease include 
elevated levels of creatine phosphokinase (CPK) subsequent to exercise in affected 
animals as compared to controls, as well as increased resting CPK, lactic dehydrogenase 
(LDH) and sorbitol dehydrogenase (SDH) concentrations (though CPK levels are not 
significantly elevated until onset of clear clinical disease symptoms) (Dent et al., 1979, 
Richards et al., 1986). 
1.5.5.  Gene Investigations to Date 
Attempts have been made to characterise the OCPMD disease model using 
traditional methods of investigation. These include histology and muscle biopsy, 
microsatellite marker analysis and western blotting to examine a fairly extensive panel 





1.6. Comparisons of the Ovine Model with Human Disease 
1.6.1.  Commonalities with Human Disease 
The distribution of lesions in OCPMD is consistent with the inherited MDs, and 
there are several similarities to specific MD diseases. Histopathology was noted by 
Richards et al. (1986) to share marked similarity to that of MyD, and the presence of 
muscle weakness with nemaline bodies in affected skeletal muscle tissue is similar to 
that observed in NM (North et al., 1997). There are notable similarities to some 
subtypes of LGMD2, and the presence of nemaline bodies was recently reported in 
LGMD2G (Paim et al., 2013). In addition, the absence of cardiac and smooth muscle 
involvement, adipose replacement in affected tissue, diaphragm skeletal muscle 
involvement, and autosomal inheritance pattern with congenital onset is consistent with 
that of NM (North et al., 1997). The congenital nature of disease presentation invites 
comparison with several of the congenital MDs and NM, but this collection of 
pathological symptoms has not previously been observed in a single human disease 
(personal communication from A/Prof. Kristen Nowak). 
1.6.2.  Differences to Human Disease 
Despite the histopathological commonalities between myotonic dystrophy (MyD) 
and OCPMD, other hallmarks of this human disease are absent in the pathology. MyD 
is associated with the persistence of action potential activity in affected muscles after 
cessation of stimulus, has a variable age of onset (between infantile up to the fourth 
decade) and with a high incidence of lenticular cataracts, myocardial lesions and 
testicular atrophy, all of which are absent in the OCPMD disease (Kakulas, 1985). 
The differences between NM and OCPMD are less pronounced, yet dystrophic 
fibers are not usually a feature of NM, and the known causative genes for this disease 
have been largely eliminated from consideration through traditional gene investigations 






Bioinformatics represents the nexus of information technology and the biological 
sciences. Recent rapid advances in computing power, coupled with similar advances in 
biotechnologies, has led to vast amounts of data being generated routinely for scientific 
(and other) studies. Traditional computing software and hardware tools have been 
outstripped by data production and complexity (Luscombe et al., 2001, Magi et al., 
2010). As a result, there is an increasing need for specialised software tools and 
platforms on which to carry out computationally-intensive analyses. These include such 
approaches as using Genome-Wide Association Studies (GWAS), Next-Generation 
Sequencing (NGS) analysis and processing, and genomic database handling, each 
described previously (Luscombe et al., 2001, Teufel et al., 2006, Magi et al., 2010, 
Moore et al., 2010, Dolled-Filhart et al., 2013). Along with these tools comes the need 
for specialised scientists with both an understanding of the underlying physiology and 
of the technology required to tease out meaningful information from the whole, giving 
rise to the critical importance of bioinformatics researchers and resources. 
1.7.1.  Origins of Bioinformatics 
The field of computational biology is the precursor to bioinformatics (Hagen, 2000). 
While its major growth came out of the human genome project and associated 
investigations into additional genomes, computers were an integral part of biological 
investigation for a full decade before DNA sequencing became feasible (Boguski, 1998) 
During the 1960’s, the expanding collection of amino acid sequences developed by 
the biological research community represented interesting problems which were best 
investigated using computationally-based approaches (reviewed by Hagen, 2000). High-
speed digital computing from weapons-research programs were becoming widely 
available and thus became an effective tool in understanding complex biological 
questions such as those posed by protein biochemists (Hagen, 2000). The development 
of the FORTRAN programs to determine the sequence of protein molecules and the 
development of algorithms to understand sequence homology and alignment accounting 
for deletions and insertions in the early 1960s represented watershed moments in 
bioinformatics development, though the field had not yet been so named (Dayhoff, 
1962, Dayhoff, 1965, Fitch, 1966). By 1970, computational biologists had developed all 
the major precursors to techniques for investigating nucleic acids, though these were all 
originally created to study proteins (reviewed by Hagen, 2000). 
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The impact the genome projects was especially felt in the growth of databanks for 
molecular biological information such as GenBank, EMBL, DDBJ, PR and SWISS-
PROT (Kanehisa and Bork, 2003). Both the diverse, large-scale data and associated 
need for sophisticated methods of handling and interrogation, and the changing 
landscape of informatics tools such as the internet and computing technology 
synergistically drove bioinformatics development in the following years (reviewed by 
Hagen, 2000). The introduction of sequence database tools such as FASTA in the early 
1980s and BLAST in 1985 were landmark events in the elucidation of useful 
information from massive data generation (Lipman and Pearson, 1985, Altschul et al., 
1990). 
The years since have seen bioinformatics grow at a pace far outstripping Moore’s 
law, as the data generation of technologies has similarly advanced, with many databases 
doubling in size every 15 months (Benson et al., 2000).  
1.7.2.  Importance of Bioinformatics to this Project 
For the required work of this project bioinformatics represents a highly necessary 
component. NGS data is far too large to utilise without such specialised tools and, when 
dealing with data from the SNP genotyping of a number of individuals, being able to 
effectively manipulate the data for interrogation is a non-trivial step.  
Carrying out alignments and variant calling from NGS data requires data 
manipulation in terms of changing file format and layouts so that specific tools can be 
applied for each discrete step in the analyses, and being able to visualise the results of 
these alignments and variants through the use of tools designed to do so requires a 
degree of expertise. For these analyses the data size and complexity is too great for 
simple approaches like manually editing a text file by hand, or opening in a spreadsheet 
tool. 
Linkage and association analysis is computationally intensive, and requires tools 
capable of conducting tests with precise control of variables, in addition to a 
computational framework on which to run the analyses. 
By leveraging the power of program scripts, specialised bioinformatics tools based 
in Unix, and the large variety of online bioinformatics resources, we were able to 
elucidate useful information from the datasets we were provided. 
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1.8. Research hypothesis and aims 
The hypothesis of my research project was that the cause of disease in the OCPMD 
flock is genetic, and that the causative gene/s could be identified through bioinformatics 
analyses and further investigated through molecular biological applications. 
This was intended to be accomplished by fulfilling the following aims: 
i.) To utilise the SNP genotype data on informative members of the OCPMD 
flock to undertake combined linkage analysis and association mapping and 
thus identify strong statistical candidates to locate a causative disease gene 
or genes. 
 
ii.) To investigate these gene and SNP candidates for the most likely candidate 
genes based on plausible biological explanations derived from the existing 
literature and database information. 
 
 
iii.) To confirm the in silico findings through homozygosity mapping of the 
affected, carrier and control Illumina whole-genome sequencing, in 
combination with the results of the preliminary GWAS from our collaborator 
at the CSIRO. 
 
iv.) Assuming the identification of a strong statistical and plausible biological 
candidate gene/s and time permitting, to investigate the disease pathology 





1.9. Significance of the Project 
The MD sheep model provides a unique opportunity to study the various associated 
pathologies, enabling much more opportunity for skeletal muscle biopsy and the 
resulting pathway analysis than has been previously possible in smaller mammalian 
models of MD. To date, the selective nature of MD pathogenesis in humans has not 
been well understood, and the development of this model to assist investigation is of 
major importance to the field. 
It also provides a unique opportunity to trial potential therapies in an animal model 
much more representative of human skeletal muscle mass than any currently available. 
With the recent advances in the sheep reference genome, we are now much more likely 
to be able to pinpoint the specific genetic involvement of this particular disease, 
providing the potential to improve our understanding of MD pathogenesis in general, in 
addition to characterizing this particular model.  
The use of a bioinformatics-based methodology provides us with the ability to use 
the existing pedigree, an improved virtual genome, and recently developed software 
infrastructure to discover the genetic basis of this unique disease presentation, and 




2. Materials and Methods 
This chapter first details an overview of the OCPMD flock along with the genetics 
and genomics considerations for the project. It then explains the bioinformatics 
workflow for investigation and details the various analyses employed to interrogate the 
genetic data available. The chapter concludes with the methodology for investigation of 
the best candidate gene using molecular biological techniques. 
2.1. The Ovine Congenital Progressive Muscular Dystrophy Flock  
2.1.1. History 
The first clinical cases were seen in 1953, but it wasn’t until 1958 that a diagnosis 
formed from the histological evidence was made (McGavin and Baynes, 1969). 
Individuals known to be affected by the disorder were bred to produce the Ovine 
Congenital Progressive Muscular Dystrophy (OCPMD) flock and their breeding 
carefully tracked and directed over decades in order to sustain an informative flock. 
During this time the disease phenotype, including pathology, was investigated through 
histological examination and clinical observation of affected individuals (Richards et 
al., 1986, Richards et al., 1988a, Richards and Passmore, 1989). The sheep were 
subsequently located to Murdoch University in ~ 1990 and cared for there, before being 
moved to the UWA Shenton Park Sheep Research Facility in 2012. 
2.1.2. Description and definition of phenotype 
The disease was reported as a congenital muscular dystrophy in 1969 (McGavin and 
Baynes, 1969) and the clinical presentation further elucidated in several papers in the 
late 1980’s (Richards et al., 1986, Richards et al., 1988a, Richards and Passmore, 1989).  
OCPMD bears similarities in presentation to the human diseases nemaline myopathy 
and myotonic dystrophy, but the specific combination of pathologies has not previously 
been observed in a single disease in humans. 
OCPMD was reported to follow an autosomal recessive inheritance (Richards et al., 
1988b). While there has been some variability reported in the severity of affection 
between individuals of the flock, a recessive inheritance with no penetrance effects in 
carriers was chosen as the best fitting analysis model. Recent evidence has suggested 
some mild pathology in certain skeletal muscles of two aged individuals (one carrier 
and one ‘unaffected’ of unknown genetic status), which was not suggested clinically 
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prior to necropsy (Report by veterinary pathologist Dr Amanda O’Hara). Additional 
necropsies in age-matched controls may be necessary to determine whether ‘mild’ 
affection in ‘carriers’ exists (also known as ‘manifesting carrier’) or if the pathologies 
exhibited were the result of ageing. 
Being a recessively inherited disease, individuals can be classified as being: 
(a) Affected (b) Carrier (c) Normal or (d) Unknown. 
 
(a) ‘Affected’ phenotype 
Defined by fulfilment of all of the following criteria, although sometimes not all 
criteria are able to be scored whilst the sheep is alive: 
(i) Noticeably stiffened gait in the hind limbs, leading to a reduced ability to run 
effectively in comparison to unaffected individuals 
(ii) Skeletal muscle tissue wasting in affected muscle groups with adipose 
replacement 
(iii) Presence of nemaline bodies in affected muscle tissues at biopsy 
(iv) Raised creatine kinase at rest, and particularly after exercise in comparison 
with unaffected individuals 
‘Affected’ individuals can be: 
(i) Descendent from two known affected individuals (100% chance). 
(ii) Descendent from an affected and carrier individual, along with phenotypic 
presentation of the disease pathology (50% chance) 
(iii) Descendent from two known carrier individuals along with phenotypic 
presentation of the disease pathology (25% chance) 
 
(b) ‘Carrier’ individuals do not show any clinical signs, and could be: 
(i) Descendent from an affected and a carrier individual (50% chance), 
(ii) Descendent from an affected and an unaffected individual (100% chance).  
 
(c) ‘Normal’ individuals do not show any clinical signs, and could be: 
(i) Descendent from two animals outside the directed pedigree (essentially 
100% chance) 
(ii) Descendent from two carrier individuals (25% chance) 
 
(d) ‘Unknown’ individuals are those that genetically could be a carrier or normal. 
They do not show any overt signs of being affected.  They might be: 
(i) Descendent from two carrier individuals (25% chance to be a carrier, 25% 
chance to be normal) 
(ii) Descent from a carrier and a normal (50% chance to be a carrier, 50% 




2.1.3. Overview of Pedigree  
While the OCPMD flock has been cared for and examined for many decades, there 
are data missing in regards to some parentage, lines of inheritance and disease state.  
The pedigree (Fig. 2.1.) has followed a careful pattern of directed breeding to ensure 
that new individuals used to continue the line of inheritance are of a known disease state 
in order to enable assumptions about the genotypes of these individuals in relation to the 
putative disease gene. 
 
Figure 2.1. Full OCPMD pedigree inclusive of all information.  
A small number of individuals have had semen samples collected and some have 
been used to artificially inseminate eggs harvested from ewes in the flock to produce the 
last generation of the pedigree. There are additional fertilised frozen eggs available for 





Figure 2.2. Pedigree of initial association analysis and homozygosity mapping. 
Some reported inheritance was demonstrated to result in impossible recombinations 
between genotypes by preliminary linkage analysis, using the software packages 
Pedstats and Merlin (Abecasis et al., 2002, Wigginton and Abecasis, 2005). This may 
have resulted from some samples being mislabelled when sent for genotyping, or 
previously to that point (e.g. lambs attributed to a certain mother may not have been; a 
mix up when the blood samples were taken). These inheritance errors necessitated using 
some ‘blank’ individuals for the pedigrees utilised in the initial analysis (Fig. 2.2.) and 
that of the final analysis (Fig. 2.3.)  
 
Figure 2.3. Pedigree of final association analysis and homozygosity mapping. Outlined individuals are the 
nuclear family used for linkage analysis. 
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Several additional individuals were genotyped on the SNP array in order to provide 
additional strength for the association and linkage analyses. This included four sib-pairs 
(Designated ‘Red 1 – Red 4’) in which one parent was of known genotype and affection 
status (the other parent was a known affected, but his DNA was not available for 
genotyping).  
2.1.4. Collection of biological samples 
The University of Western Australia Ethics Committee approved the maintenance of 
the flock, and all procedures performed on members of the flock associated with this 
project. Blood samples were collected from all pedigree members during the 
maintenance of the flock in order to enable genotyping. Semen samples were collected 
from certain males in recent generations to facilitate directed breeding through artificial 
fertilisation at later dates, and in particular to ensure preservation of the flock. 
Samples of skeletal muscle tissue from two affected sheep (#398 and #74), one 
known carrier (#1563) and one clinically unaffected sheep with unknown genotype 
(#229) were collected at post-mortem and preserved by snap-freezing in liquid nitrogen 
and stored at -80 
o
C.   
2.1.5. Histology and biomarkers 
The gold standard method for determining the affection status of any individuals 
from this flock has been biopsy of soleus skeletal muscle tissue to confirm pathology, as 
this muscle shows consistent morphological changes in all affected individuals 
(Richards et al., 1986).  Additionally it is a muscle that can be excised during 
anaesthesia and not cause any detrimental effect on the sheep afterwards. Affected 
soleus muscle is characterised by skeletal muscle wasting and progressive fibrous and 
fatty tissue replacement, and the presence of nemaline bodies under histological 
examination. 
Creatine kinase was generally elevated for affected individuals beyond that of 
unaffected individuals at rest or after exercise (Richards et al., 1986). However, the 
levels of this enzyme are not considered a reliable enough measure of disease status due 
to a reduction in the degree of creatine kinase elevation as the disease progresses (e.g. 
an exhaustion of the skeletal muscle that is degenerating, and therefore less release of 




2.2. Genetics and Genomics 
2.2.1. Sheep Genome Project 
The sheep genome project is ongoing and not finalised, however the latest build 
released for research purposes is version 3.1. (Archibald et al., 2010). There is no SNP 
database available such as dbSNP, and the annotation is not widely available for 
interrogation at this time, however it is available for direct download 
(http://www.livestockgenomics.csiro.au/sheep/oar3.1.php). It has been utilised in this 
project to assist investigation into genes implicated by linkage, association analysis and 
homozygosity mapping. Reported genes are based on predicted protein coding 
sequences. 
The sheep reference genome version 3.1. was provided by Dr. James Kijas in 
FASTA format. 
2.2.2. SNP Array 
As part of the international sheep genome consortium’s (ISGC) sheep reference 
genome work, an array containing 49 034 high quality SNPs for use in the investigation 
of sheep genetics was developed 
(http://www.sheephapmap.org/images/pag09_dalrymple.pdf). This was used in this 
project and will be referred to as ‘the SNP array’.  
Genotyping of samples on the SNP Array was performed by Dr. James Kijas’ 
laboratory team and the results provided to this project. The array has 53 903 individual 
SNPs, for which 49 034 passed the laboratory quality control (QC). For each genotyped 
individual a file containing the genotyping results in PLINK format (.ped) and a file 
containing the genomic map position of each SNP (.map) was provided. A file 
containing the full collection of SNPs used for genotyping (.dat) was generated from the 
provided files. 
The positions of the included SNPs were provided in the SNP genomic annotation 
file 
(http://www.livestockgenomics.csiro.au/sheep/oarv3/Oarv3.1.50kSNP.position.gff3). 






SNP genotypes from 9 informative affected and 5 informative carrier individual 
SNP genotypes were made available for analysis. In addition, the genotypes of several 
individuals classified ‘unknown’ were provided (Fig. 2.2.).  
Final Analysis 
After genotyping of additional members of the flock was performed, SNP genotypes 
from 14 informative affected and 6 informative carrier individual genotypes were 
available for analysis, including those available in the initial analysis. In addition, 
several genotypes for ‘unknown’ individuals were provided (Fig. 2.3.). 
2.2.3. Whole-Genome Sequencing 
Two individuals from the OCPMD flock were whole-genome sequenced as part of a 
larger project conducted on 50 sheep by the ISGC on the Illumina platform and the 
results provided to this project. These sequences were aligned to the sheep reference 
version 3.0. using SAMtools and mpileup and provided in .bam format. 
The binary files for these aligned sequences, being one affected individual (#398) 
and one carrier individual (#1560) were provided to this project along with one ‘normal’ 
merino sheep aligned to the same reference.  These were of approximately 8x coverage. 
2.3. Bioinformatics 
Bioinformatics analysis required manipulation of data resources into the appropriate 
format for software utilisation. This process also involved a large degree of quality 
control and the adjustment of research strategies based of the resulting information. The 
workflow of analysis and candidate selection strategy was adjusted based on the quality 
of and limitations on the provided data. 
2.3.1. Analysis 
The goal of the bioinformatics analysis workflow (Fig. 2.4.) was to cast a wide net 
at each phase of the analysis (homozygosity mapping, association analysis, and linkage 
analysis) in order to develop a large candidate geneset for the putative disease mutation. 
All of the ‘best candidates’ from each approach were included in the geneset. The 
results of each of these approaches were then cross-referenced to find candidates for 
which multiple lines of evidence supported further examination, and those which were 
highly significant under one approach or moderately significant under multiple 
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approaches investigated by interrogation of published literature and publically available 
databases for a biologically plausible involvement in the OCPMD pathology. 
 
Figure 2.4. Flowchart for bioinformatics analyses leading to candidates for further investigation.  
2.3.1.1. Homozygosity Mapping 
Homozygosity mapping was carried out using a custom tool, written in perl: the 
‘Homozygosity_Mapper’ (see appendix V for source code). While there are existing 
homozygosity mapping tools available, many of the tools are designed for human data 
only (e.g. fixing the expected number of chromosomes) and do not handle complex 
pedigrees, such as our OCPMD data. Thus we determined that it would be best to 
construct out own tool to perform this task. 
The homozygosity mapper interrogated the dataset of SNP genotypes for 
consecutive sequences of homozygous SNPs, ignoring missing values, and reported all 
consecutive runs over an input threshold value for those of the specified subset. This 
included the genomic positions of SNPs. By specifying the included individuals by 
disease state I was able to discover regions of homozygosity specific to affected 
individuals within the pedigree. By including a ‘wobble factor’ into the tool I was able 
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to examine potential runs of homozygosity with an input number of ‘mismatches’ 
(SNPs which were homozygous in all but 1 or 2 individuals, for example – depending 
on the  wobble value). This loosened the specificity, allowing for a single (or more) 
genotype error or mismatch, while identifying potential long stretches of homozygous 
markers which would otherwise not be observed. 
The mapper then accessed the v. 3.1. sheep reference genome annotation file and 
used the reported SNP and gene positions to automate the reporting of which genes 
were included in these regions of homozygosity.  
Initial Analysis 
The initial analysis included 9 affected individuals to identify homozygous runs in 
all affected, and 5 carriers to determine if these homozygous regions were shared 
between both the affected and carrier groups (Fig. 2.2.).  
The longest run of homozygosity observed in the dataset was with the following 
command: 
 
This specified that only affected individuals (2) were to be included in the analysis, 
no wobble factor (0), and the reporting of sequential homozygous SNPs in a run of ≥8 
(8).  
The next longest runs of homozygosity in the dataset were observed with the 
following command: 
 
This had the same parameters as the previous search, but reported all runs of 
homozygous SNPs ≥5. 
To discover whether these regions of homozygosity were distinct to the affected 
individuals commands of the same parameters but specifying carriers only were also 
input: 
$ perl Homozygosity_Mapper.pl 
InitialPedigreeWithBlanks.ped 
SNP50_3.1.ReferencePositions.map 48808SNPs.dat 2 0 5 
 
$ perl Homozygosity_Mapper.pl 
InitialPedigreeWithBlanks.ped 





The results of these analyses were then compared. Regions of homozygosity shared 
between carriers and affected were still considered for candidate gene selection, but less 
weight given to the genes within the shared regions.  
Final Analysis 
The final analysis included 14 affected individuals to identify homozygous runs 
specific to the affected and 6 carriers to determine if these homozygous regions were 
shared between both the affected and carrier groups (Fig. 2.3.).  
The longest run of homozygosity was observed with the following command: 
 
The next longest runs of homozygosity were observed with the following command: 
 
As with the initial analysis, the same commands were input specifying carrier 
individuals and the results compared with that of the affected to check whether the 
regions of homozygosity were shared by all the flock, or just the affected individuals.  
The genes present in regions of SNP homozygosity specific to the affected 
individuals at the top two thresholds were included in the candidate geneset for further 
investigation. Homozygous runs which were only present in the carriers were 
discounted, while those shared by both the carriers and affected sheep were included in 
the candidate geneset, but given lesser weight than those limited to the affected 
individuals. 
2.3.1.2. Association using PLINK 
For the association analysis, we chose to use the PLINK software package (Purcell 
et al., 2007). PLINK is very widely used for GWAS analysis, and is capable of 
$ perl Homozygosity_Mapper.pl FinalPedigree.ped 
SNP50_3.1.ReferencePositions.map 48808SNPs.dat 2 0 5 
$ perl Homozygosity_Mapper.pl FinalPedigree.ped 
SNP50_3.1.ReferencePositions.map 48808SNPs.dat 2 0 6 
$ perl Homozygosity_Mapper.pl 
InitialPedigreeWithBlanks.ped 




performing family-based association analysis and handling the extended pedigrees from 
the OCPMD flock. 
Initial Analysis 
The initial association analysis using PLINK was limited by a low sample size and 
the exclusion of individuals that had an unclear phenotype or unknown genotype as 
related to the putative disease gene.  
As already described, of those individuals that were genotyped and of known 
phenotype 9 were affected and 5 were carriers. 
The recessive model was included in the analysis in accordance with the reported 
inheritance pattern for this disease.  
Despite being part of the same large pedigree, in most cases SNP genotyped 
individuals were not connected into nuclear family units; to enable computational 
processing the ‘discrete families’ option was used. This broke the broader pedigree into 
small family units, but the analysis was essentially that of disconnected individuals.  
As the map file for this analysis consisted of only 3 columns, the option of map3 
was specified. 
The included option within PLINK to specify sheep as the species was employed. 
The data did not meet the assumption of minimum cell count number (≤5) for the χ2 
test in regard to the control (carrier) individuals. For this reason the option of reducing 
the minimum count in a cell to 0 was used.   
Due to the small sample size, relatively sparse coverage of the genome, and the 
inability to use a test assuming the relatedness of these individuals, control for multiple 
testing was not able to be employed. This limited the investigation to being exploratory. 
Both adaptive and discrete permutation testing were attempted, but resulted in no single 
SNP reaching an adaptive significance level smaller than a p-value of 0.3. For this 
reason the control for multiple testing errors was created by the complementary 
bioinformatics analyses being mutually supportive of candidate gene selection, rather 






While the final association analysis had greater numbers than the initial, the sample 
size was still a lower number than would have been ideal, and the exclusion of 
individuals who had unclear phenotype or unknown genotype as related to the putative 
disease gene further decreased the number of individuals for testing. This analysis 
included the members of the initial analysis.  
Of those individuals which were genotyped and of known phenotype 14 were 
affected and 6 were carriers. 
The recessive model was again included in analysis in accordance with the reported 
inheritance pattern for this disease.  
As before, the discrete families option, sheep option, and reduction in minimum cell 
size to 0 was used. The analysis was run with the following command: 
 
For both the initial and final dataset, the results of the association analysis were 
extracted and those meeting a p-value significance level of ≤0.05 had their 
chromosomal base position and gene within which they occurred (or closest gene and 
distance to gene) inserted into the results. This was carried out by use of a custom tool 
written in perl which accessed the genome annotation file and SNP position file, called 
the ‘Plink_Parser’ (see appendix VII for source code). 
Any SNP which did not occur within a gene or within a close distance was excluded 
from further analysis, as were any SNPs which occurred on the X chromosome, as the 
disease is autosomally inherited. SNPs which were found significant in the results of the 
initial dataset but not that of the final dataset, or were found to be less significant in the 
final dataset than initially, were excluded from the results. While the two analyses did 
$ plink --ped FinalPedigree.ped --sheep --model --model-
rec --dfam --cell 0 -–map 
SNP50_3.1.ReferencePositions.map 
$ plink --ped InitialPedigreeWithBlanks.ped --map3 --




not satisfy the assumptions of independent testing, the time limitations of the project 
necessitated using the initial analysis to identify gene candidates prior to additional SNP 
array results being available. Thus, the initial and final analyses were used to 
complement one another. Those which were only slightly more significant in the final 
analysis than the initial results were excluded, in favour of those for which the p-value 
was decreased more substantially (~90% of the SNPs found to be more significant were 
of a p-value 50% smaller than in the initial dataset). 
Two copies of these results were then made; one sorted by p-value and one sorted 
by gene name, in order to investigate not only the top significant SNPs but also any 
genes which had multiple significant intragenic SNPs. 
The allele distribution between affected and unaffected individuals was examined 
for all significant SNPs for consistency with the known inheritance pattern. The genes 
within which SNPs were significant under the recessive model, and passed any of the 
other respective criteria, were included in the candidate geneset for further 
investigation. 
2.3.1.3. Linkage analysis 
For the linkage analysis, I chose to utilize the Merlin software package (Abecasis et 
al., 2002). Merlin is a widely used software package for conducting genetic linkage 
analyses on nuclear and extended pedigrees. Based on allelic inheritance, this approach 
was severely limited by the disconnected nature of the genotyped individuals in the 
flock. Because of this, the analysis was based on the only present nuclear family group 
(#398, #30, #RED1-4), one parent of which was not genotyped, which did not provide 
sufficient power to be used in candidate discovery. The linkage analysis was thus not 
able to be used in identification of candidate genes but instead to provide additional 
evidence for or against candidates identified by homozygosity mapping and association 
analysis.  
Linkage analysis using the nuclear family (inclusive of #30, #398 and RED #1-4) 
with a parametric, recessive model, using a disease rarity of 0.0001, 0.0, 0.0, 1.0 (full 
penetrance, no penetrance effects) yielded a maximum possible LOD score of only 0.66, 




The option ‘markerNames’ was used to report the specific markers involved rather 
than their map positions.  
 
The options of ‘bits 40’ and ‘megabytes:25000’ were used to increase the available 
memory for the program in order to handle the complexity of the extended pedigree.  
 
The ‘model’ option was included in order to run the analysis based on the 
parameters of the defined recessive model. The analysis was run with the following 
command: 
 
Attempted analysis of the wider genotyped pedigree was not informative. 
2.3.1.4. Identification of the Candidate Geneset 
Genes within the identified regions of homozygosity for affected individuals of the 
pedigree were included in the candidate geneset. Also included were genes within 
which a SNP was found to be significantly associated with disease using the association 
analysis. The limitations of the linkage analysis prevented the use of this approach to 
select SNPs for the candidate geneset, and they were instead used as supporting 
evidence to assess the selected candidates resulting from the association analysis and 
homozygosity mapping. A negative or neutral LOD score towards the SNPs within a 
particular gene candidate was counted against its credibility as a candidate, while a 
positive LOD score counted towards the same. 
2.3.1.5. Biological Plausibility Investigation Candidates 
All genes in the candidate geneset were then investigated using online resources and 
databases to find those which may be implicated in causing skeletal muscle-specific 
conditions.  
The positioning of each SNP and gene was confirmed by accessing the online 
resource for the sheep genome v. 3.1.  
Each gene under investigation was searched in the Online Mendelian Inheritance in 
Man (OMIM) database (McKusick, 2013) and in the Genecards database 
(www.genecards.org) for known gene expression profiles of the gene (e.g. was the gene 
$ merlin -d 48808SNPs.dat -p NuclearFamily.ped -m 
3LineMapFile.map --markerNames --bits 40 --model 




expressed in skeletal muscles), any biologically plausible mechanism by which it may 
have resulted in the disease, and for known disease associations which may fit the 
disease phenotype. 
Google, Google Scholar and Pubmed were then interrogated for each candidate 
gene, and the following key words, in an attempt to find any relevant published data 
which might explain the disease phenotype: myotonic dystrophy; muscular dystrophy; 
nemaline myopathy; skeletal muscle; myopathy; dystrophy. 
The best candidate from these complementary approaches was then chosen for 
follow-up using molecular biology. 
2.3.2. Data Manipulation 
2.3.2.1. SNP Array Data Manipulation 
As the sheep reference genome was updated through the continued efforts of the 
ISGC the genomic positions of some SNPs was changed from previous iterations.  
Large numbers of reported impossible recombination patterns between the offspring 
of #1563 and #1560 using pedstats and Merlin dictated the adjustment of the familial 
relationships then replace these individuals with ‘blanks’ (individuals with no reported 
values for SNP genotypes).  
2.3.2.2. SNP validation 
The genomic positions included in the provided .map files were based on the version 
1.0 sheep reference genome. For analysis, these positions were updated to the version 
3.1. genomic positions. This was carried out by extracting the 3.1. positions from the 
provided genome annotation file using a custom perl script and using PLINK to update 
the map and base pair chromosomal positions to the 3.1. reference version. This resulted 
in a number of SNPs changing position to unaligned scaffolds and the total number of 
SNPs in chromosomal positions on the reference genome to be 48 808. 
2.3.2.3. PLINK 
For association analysis the PLINK software package was utilised (Purcell et al., 
2007, Purcell). For initial analysis, the adjusted files were modified to follow the 
PLINK format for missing values and uninformative individuals were trimmed from the 




For linkage analysis the Merlin software package was utilised (Abecasis et al., 
2002). The provided SNP data files were modified to follow the Merlin format using 
command line interface. The map files provided used chromosomal position and were 4 
column files. Merlin requires the position in cM and 3 columns only. The cM 
positioning was approximated by dividing the chromosomal positioning by 1 000 000 
and the extra column removed. Uninformative individuals were trimmed from the 
analysis. 
2.3.2.5. Genome Sequencing 
The provided genome sequencing files and annotation file had a different 
nomenclature for chromosomes than the reference FASTA sequence. The reference was 
modified using a perl script utilising the FASTA reader package. 
The provided BAM files for individuals #398 and #1560 were realigned to the 
reference genome using BWA-MEM with the intention of improving the accuracy of 
alignment by using more recent tools than that used by the laboratory of Dr. James 
Kijas (Li, 2010). The alignment was validated using picard-tools and the validated SNP 
array (49 034) used as the database of known polymorphisms in order to put the 
realignment through the GATK workflow to call variants (McKenna et al., 2010, 2013). 
The lack of an indel database for sheep prevented taking these realignments through to a 
final file for analysis, and this path of investigation was abandoned in favour of using 




2.4. Molecular Biology 
In order to strengthen the hypothesis of the prime candidate ROCK2 as a causative 
disease gene for the OCPMD flock, additional investigation was undertaken at the 
molecular biological level. This included PCR amplification of the candidate gene 
cDNA and sequence analysis. 
 
Figure 2.5. Flowchart for molecular biological investigation of prime candidate gene for the OCPMD 
pathology.  
2.4.1. Primer Design 
The genomic sequence at the position of ROCK2 as reported by version 3.1. of the 
reference ovine genome was not adequately annotated and did not appear to match with 
the expected structure of ROCK2. Moreover the number of exons in the gene, being 32, 
and the size of the interspanning introns made screening this gene based on genomic 
DNA problematic. For this reason, the cDNA was targeted. The ROCK2 cDNA 
sequence for sheep is not published. 
Because of this, the conservation of the amino acid and nucleotide sequence across 
species was investigated using the software package Alamut v. 2.3, with NCBI build 36. 
While the amino acid sequence was found to be highly conserved across mammalian 
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species, the sequence of nucleotides was found to be only generally conserved in 
mammals.  
Primers for this ovine study were therefore designed based on conserved regions 
identified within the ROCK2 human, mouse and bovine cDNA sequences, as derived 
from the genome builds available in Ensembl (Flicek et al., 2013). The genome builds 
and links to each ROCK2 cDNA sequence are provided in Table 2.1. Where 100% 
conservation between all three cDNA sequences was not possible, primers were instead 
designed in locations where 100% conservation existed between the bovine and human 
cDNAs, and minimal mismatches were identified in the mouse cDNA sequence. At the 
mismatch positions redundant nucleotides were used. These primer pairs (A-F, Table 
2.2.) covered approximately 95% of ROCK2’s cDNA and were designed to be 
amplified at similar conditions to speed laboratory workflow.  Additional primer sets (G 
& H, Table 2.2.) were designed at the terminus regions of the gene in order to attempt 
complete coverage of the cDNA sequence. 
Table 2.1. Source of cDNA for ROCK2 human, mouse and cow species. 


















The primers were designed using the publically available Primer-BLAST tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) (Ye et al., 2012) and additionally 
validated using the Sigma Aldrich design tool 
(http://www.sigmaaldrich.com/configurator/servlet/DesignTool?prod_type=STANDAR
D) in order to ensure that the resulting oligonucleotides had minimal primer dimer and 




Designed primer pairs were as follows: 
















B 5-9 F: GCCTGGTGGAGACCTTG 
R: CTGCTGTCTATGTCACTGCTG  
630 62.0 
61.3 


























*Redundant bases in red; Start codon of ROCK2 in bold 
2.4.2. RNA Extraction 
Total RNA was extracted from the gracilus muscle (not affected in diseased 
individuals) of an affected (#398) and a carrier (#1563) sheep from the OCPMD flock. 
RNA was also extracted from the soleus muscle of the carrier but was not available 
from affected sheep as the soleus muscle is always affected (and hence has turned to fat) 
in aged diseased individuals. RNA extractions were performed using the RNEasy 
Fibrous Tissue Mini Kit (Qiagen) in accordance with the manufacturer’s protocol 
(Qiagen, 2010).  RNA concentration and quality (Abs. 260/280) was determined by a 
NanaDrop1000 (ThermoScientific).  
2.4.3. cDNA synthesis 
cDNA was synthesised from total RNA by reverse transcription using Superscript 
III First-Strand Synthesis System for RT-PCR (Life Technologies) and random 
hexamers (Invitrogen), following the manufacturer’s protocol. The success of cDNA 
synthesis was confirmed by successful PCR amplifications of the ROCK2 gene and 
electrophoresis. 
2.4.4. PCR Amplification 
For all amplification reactions the touchdown protocol was used (Korbie and 
Mattick, 2008). Each primer pair was initially trialed for PCR using the touchdown 
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program targeted to 63
o
C, with one reaction containing and one not containing Q 
solution. Amplification of primer pair G was also attempted using a touchdown program 
targeted to 68
 o
C and a touchdown program targeted to 70
 o
C after failing to amplify at 
the touchdown 63
 o
C conditions.  All PCR reactions were of 10 L. Each reaction was 
as follows: 
Table 2.3. PCR components for targeted amplicons within ROCK2 
 With Q Solution Without Q Solution 
Component Volume (L) Volume (L) 
H2O 4.6 6.6 
10x buffer 1.0 1.0 











cDNA 1 1 
Total 10 10 
 
cDNA from the carrier’s soleus and gracilus, and the gracilus of the affected sheep 
was used for PCR using all primer pairs. As the primers were designed to have 100% 
homology to the human sequence, for those primer pairs that failed under the initial 
PCR conditions, human cDNA (synthesised from RNA extracted from human skeletal 
muscle) was subsequently used as positive control to determine whether primer design 
or PCR conditions were the cause of failure. 
2.4.5. Electrophoresis of PCR products 
Unless otherwise specified, all PCR products were electrophoresed through a 1% 
agarose gel (containing 20 L ethidium bromide / 400 mL agarose) with sodium borate 
buffer (0.4g NaOH /L; 2.4g H2BO3/1L; pH 7.0) using 3 L of 4X loading buffer with 3 
L of reaction product, and size determined against a 100 bp ladder (Invitrogen). 
2.4.6. Sequencing of Candidate Gene 
PCR products were purified by pipetting through a purification tip (Diffinity 




Table 2.4. Sequencing reaction components for ROCK2 PCR products. 
Component Volume (L)  
Big dye terminator mix 2.0 
Sequencing buffer 2.0 
Primer (forward OR reverse @ 50 
ng/l)  
1.0 
Template DNA 1.0-5.0* 
Water variable 
Total 10  
* Volume dictated by intensity of PCR products after electrophoresis. Strong 
intensity reduced the volume to 3 L while a lesser intensity increased the 
volume to 5 L 
 
 
Table 2.5. Thermocycler protocol for sequencing reaction. 
Step Condition 
1 96oC for 1 minute 
2 96oC for 30 seconds 
3 50oC for 30 seconds 
4 60oC for 4 minutes 
5 Goto step 2 24x 
 
Each sequencing reaction was then taken through the following post-sequencing 
cleanup process: 
1. Add 2.5 L EDTA, 2.5 L 3M sodium acetate, 25 L 100% EtOH. 
2. Vortex well and sit at room temperature for 15 minutes. 
3. Centrifuge at 14000 rpm for 20 minutes. 
4. Discard supernatant without disturbing pellet using pipette. 
5. Wash well with 200 L of 70% EtOH, dislodging pellet. 
6. Centrifuge at 14000 rpm for 5 minutes. 
7. Discard supernatant without disturbing pellet using pipette. 
8. Dry in heating block @ 55 oC for at least 30 minutes or until dry. 
The resulting samples were sent to the Lotterywest State Biomedical Facility: 
Genomics for sequencing. 
2.4.7. Sequence Analysis 
The sequencing results were aligned to the bovine cDNA sequence as reference for 
ROCK2, as derived from the Ensembl Cow release 73 (Flicek et al., 2013). Some 
sequencing results were not of sufficient quality to align to the reference and were 
automatically trimmed for quality at each end based on program default settings. This 
allowed most remaining sequences to be aligned to the bovine cDNA but several were 
still of insufficient quality to do so.  
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The aligned sequences were then analysed using the Codoncode aligner v.4.03 
(CodonCode Corporation, 2013) in order to identify a possible homozygous mutation in 
the affected individual and a heterozygous mutation in the carrier. The base calls and 
chromatogram for the forward and reverse sequence of each PCR product was inspected 
for quality and divergence from the bovine cDNA reference or from consensus with the 







Bioinformatics methods were employed to find the best candidate gene/s for follow-
up in the laboratory. For both homozygosity mapping and the association analysis, an 
initial analysis was carried out on 14 informative individuals and a subsequent final 
analysis carried out on 20 informative individuals (inclusive of the first sample group), 
when additional samples became available.  
SNP homozygosity mapping was carried out to find homozygous regions of the 
genome in the affected individuals, while association analysis of the OCPMD SNP 
genotypes was conducted in order to determine statistically significant markers (and 
thus genes) of interest as potentially causative of the pathology.  
Linkage analysis was performed using the SNP genotypes in order to provide 
additional evidence for any resulting candidates. While ideally we would utilize results 
from linkage analysis firstly, followed by association analysis only in those regions 
where linkage signals were detected thus maximizing statistical power and reducing the 
number of tests required, this was not possible due to lack of informative families (as 
noted earlier, and described further in Discussion). The candidate geneset was then 
investigated through interrogation of publically available databases and published 
literature for biological plausibility in order to identify best candidates for down-stream 
molecular biological analysis. 
 The ROCK2 gene was identified as a priority candidate for further investigation 
using molecular biological techniques. Primers for cDNA amplification were designed 
in an overlapping manner based on conserved regions on the human, mouse and bovine 
cDNA sequences. RNA was extracted from gracilus skeletal muscle from an affected 
individual (#398) and from the gracilus and soleus skeletal muscle for a carrier sheep 
(#1563). cDNA was synthesized from all three RNA extractions and PCR amplification 
using various primer pairs was attempted for all samples. All successful amplifications 
were sequenced and the results analysed. 
3.2. Results from Bioinformatics Analyses 
Bioinformatics analyses included homozygosity mapping, association analysis and 
linkage analysis.  These complementary approaches resulted in the selection of 
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approximately 50 to 100 candidate genes for further investigation from the published 
literature and publically available database resources. 
3.2.1. Homozygosity Mapping 
Homozygosity mapping was carried out using the SNP genotypes of the flock to 
determine regions of the genome that were homozygous in the affected individuals, as 
described in Section 2.3.1.1. 
 
Initial Analysis 
Table 3.1 indicates the longest regions of homozygosity observed in the initial 
dataset, derived from 14 informative individuals. 
Table 3.1. Longest homoyzgous genomic regions observed in the SNP genotypes of the affected individuals in 













End   Chr3:20116222 
8 9/9 0/5 219662 PQLC3 
ROCK2 
Start Chr25:19167503 
End   Chr25:19438048 
6 9/9 1/5 270545 NRBF2 
JMJD1C 
Start Chr3:11661403 
End   Chr3:11916080 
6 9/9 4/5 254677 Uncharacterised 
Start Chr13:55866953 
End   Chr13:56010691 
5 9/9  143738 CDH26 
SYCP2 
Start Chr11:49904840 
End   Chr11:50045164 
5 9/9  140324 CCD57 
FASN 
LRR45 
* Sharing homozygous SNP genotype region  
 
The run of homozygosity containing ROCK2 was the longest observed in the initial 
dataset. The genes within the second and third longest runs of homozygosity were also 
put forward for additional investigation. 
Final Analysis 
Table 3.2. indicates the longest regions of homozygosity observed in the final 





Table 3.2. Longest homozygous genomic regions observed in the SNP genotypes of the affected individuals in 














End   Chr3:20116222 
6 14/14 2/6 126626 PQLC3 
ROCK2 
Start Chr25:19270565 
End   Chr25:19438048 
5 14/14 2/6 167483 JMJD1C 
Start Chr11:49904840 
End   Chr11:50045164 




End  Chr13:56010691 
5 14/14 6/6 143738 CDH26 
SYCP2 
* Sharing homozygous SNP genotype region  
 
The longest observed run of homozygous SNPs for affected individuals in the final 
dataset covered 6 sequential SNPs, encompassing 126626 bp. This region, covering 
SNP 3 – 6 (Table 3.3) while shorter than that seen in the initial dataset, covering SNP 1 
– 8 (Table 3.3), reassuringly still included ROCK2, suggesting its viability as a potential 
candidate of interest. In this larger dataset, with the shorter region of homozygosity, 
there were 2 carriers out of 6 who shared the homozygous SNP genotypes with the 14 
affected. The next longest run of homozygous SNPs observed were of 5 markers in 
length. There were 2 of these regions observed and all genes involved put forward for 
further investigation. 
The SNP genotypes for all informative individuals of the flock for the ROCK2-
containing homozygous SNP region were extracted from the SNP genotype pedigree 
file using the custom perl script “Haplotype_Extractor” (see appendix VI for source 
code). 
Table 3.3. SNP genotypes of the affected individuals within the ROCK2-containing run of homozygosity 
ID Father Mother Sex*    1       2       3       4       5      6       7        8 
398 1565 1564 2 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
1242 1137 1112 1 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
1406 1137 1108 1 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
1409 1137 1111 2 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
1279 1103 1128 1 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
1503 1103 1107 1 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
1508 1103 1105 2 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
1512 1103 1134 2 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
1518 1103 1132 2 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
Red1 30 398 1 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
Red2 30 398 1 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
Red3 30 398 1 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
Red4 30 398 2 G/G  G/G  G/G  A/A  G/G  G/G  A/A  G/G 
74 1560 1564 1 G/G  A/G  G/G  A/A  G/G  G/G  A/A  G/G 




Table 3.4. SNP genotypes of the carrier individuals within the ROCK2-containing run of homozygosity 
ID Father Mother Sex* SNPs+    1       2       3      4       5       6       7      8 
1560 130 1512 1  A/G  A/G  G/G  G/A  A/G  A/G  A/A  G/G 
1561 131 1508 2  G/G  A/G  G/G  A/A  G/G  G/G  A/A  G/G 
1563 131 2001 2  G/G  A/G  G/G  A/A  G/G  G/G  A/A  G/G 
1107 0 0 2  G/G  A/G  G/G  G/A  G/G  A/G  A/G  G/G 
1119 0 0 2  G/G  G/G  A/G   0/0  G/G  A/G  A/G  G/G 
207 1560 1563 2  A/G  A/G  G/G  G/A  A/G  A/G  A/A  G/G 
*1 Male; 2 Female; +highlighted SNPs represent those homozygous in carriers #1561 and #1563 
 
The SNP genotype observed for SNP 2 in #74 (highlighted in yellow) was 
responsible for shortening the length of the homozygous region in affected individuals 
of the flock. The inheritance of this allele from #1560 and #1563 is consistent with this 
result. 
3.2.2. Association Analysis 
Genome-wide association analysis was conducted on the SNP genotypes of the 
flock, using PLINK, to determine whether SNPs which showed statistically significant 
correlation (P<0.05) to the disease state under a recessive inheritance model, as 
described in Section 2.3.1.2.  
Initial Analysis  
The initial analysis found 371 SNPs which met this significance level and were 
within a gene. Of these, 5 were x-linked and thus excluded due to the autosomal 
inheritance pattern. Being a slightly larger sample size and thus more informative, the 
final analysis, inclusive of the individuals of the initial dataset, found 415 SNPs which 
met the 0.05 significance level. Of these 4 were x-linked and were thus excluded. The 
top 20 SNPs by p-value are included Table 3.5., as is the SNP within ROCK2 also found 




Table 3.5. Top SNPs by significance for initial association analysis. 









1 OAR12_83564723.1 Uncharacterised 8/1 0/5 0.001281 
2 OAR2_195165011.1 PTPN4 9/0 1/4 0.001499 
3 s42749.1 MAN2A1 7/0 0/3 0.001565 
4 s53402.1 FTCD 0/9 3/1 0.003054 
5 s09120.1 PPP1CC 6/1 0/5 0.003415 
6 OAR1_135764540.1 TAK1L 7/2 0/5 0.005289 
7 OAR1_38581202.1 DOCK7 7/2 0/5 0.005289 
8 OAR2_219701580.1 ADAM23 7/2 0/5 0.005289 
9 OAR1_65172267.1 SYDE2 0/9 3/2 0.008752 
10 OAR10_49941391.1 KLF12 9/0 2/3 0.008752 
11 OAR12_82572003.1 C1ORF53 0/9 3/2 0.008752 
12 OAR14_29971688.1 CDH8 0/9 3/2 0.008752 
13 OAR17_45018430.1 GRIA2 0/9 3/2 0.008752 
14 OAR23_36959489.1 GREB1L 0/9 3/2 0.008752 
15 OAR23_59623047.1 Uncharacterised 0/9 3/2 0.008752 
16 OAR3_123897974.1 PTPRQ 0/9 3/2 0.008752 
17 OAR8_56910466.1 THEMIS 0/9 3/2 0.008752 
18 OAR8_58134022.1 LAMA2 0/9 3/2 0.008752 
19 OAR8_58181648_X.1 LAMA2 0/9 3/2 0.008752 
20 s03652.1 GLRB 0/9 3/2 0.008752 
 … … … … … 
=200 OAR3_21684794.1 ROCK2 9/0 3/2 0.04042 
*’Affected’ genotype wherein tested alleles are homozygous  
 
Table 3.6. Association analysis results of SNPs within the ROCK2 gene in the initial dataset. 






Chi2 df p-value 
3 OAR3_21684794.1 A G Recessive 9/0 3/2 4.2 1 0.04042 
3 OAR3_21630699.1     A G Allelic 0/18 3/7 6.048 1 0.01392 
 
OAR3_21684794.1 was found to be significant within the initial dataset at a p-value 
of 0.04042, ranking at =200 of 366 significant SNPs, with all 9 affected individuals 
possessing the AA alleles (Table 3.6.). 
Final Analysis 
After additional genotyping, the new dataset provided further results, changing the 
significance of a number of SNPs and causing a number to become less significant than 
they were in the initial dataset. Table 3.7 summarises the top 20 SNPs by p-value, along 




Table 3.7. Top SNPs by significance for final association analysis. 









1 OAR12_83564723.1 Uncharacterised 12/2 0/6 0.000336 
2 OAR2_195165011.1 PTPN4 14/0 2/4 0.000636 
3 OARX_29188769.1 Uncharacterised 11/3 0/6 0.001209 
4 s43015.1 CCL26 11/3 0/6 0.001209 
5 OAR3_193744872.1 IFT27 10/3 0/6 0.001799 
6 s10237.1 IL21R 10/3 0/6 0.001799 
7 s09120.1 PPP1CC 10/1 1/5 0.002205 
8 OAR10_33307197.1 Uncharacterised 12/2 1/5 0.00301 
9 OAR10_69032148.1 GPC5 12/2 1/5 0.00301 
10 OAR10_25988324.1 NBEA 10/4 0/6 0.003415 
11 OAR24_30139569_X.1 MRPS17 10/4 0/6 0.003415 
12 OAR24_30146533.1 MRPS17 10/4 0/6 0.003415 
13 OAR3_19616550_X.1 KIDINS220 10/4 0/6 0.003415 
14 OAR16_71436671.1 ADCY2 0/14 3/3 0.004108 
15 OAR17_45018430.1 GRIA2 0/14 3/3 0.004108 
16 OAR17_75701731.1 INPP5J 0/14 3/3 0.004108 
17 OAR18_16433946.1 AGBL1 0/14 3/3 0.004108 
18 OAR23_36959489.1 GREB1L 0/14 3/3 0.004108 
19 OAR3_35192406.1 DTNB 0/14 3/3 0.004108 
20 OAR4_26645098.1 TSPAN13 0/14 3/3 0.004108 
 … … … … … 
=128 OAR3_21684794.1 ROCK2 14/0 4/2 0.02278 
*’Affected’ genotype in which both tested alleles were homozygous 
 
Of the 411 included significant SNPs in the final dataset, 158 SNPs also appeared in 
the results of the initial dataset and were found to improve in significance by 
approximately 50 %. Twenty nine of the SNPs in the final analysis were found to be 
less significant than in the initial dataset and were thus excluded. Six were only slightly 
more significant (compared to the 158 which were in general ~twice as significant) and 
excluded. This provided 376 SNPs of significance which occurred within a gene and 
were found to be significantly associated with the disease, 158 of these being 
considered part of the ‘overlap set’. All of the genes in which these SNPs occurred were 
placed into the candidate geneset for further investigation, and the overlap set given 
additional scrutiny. 
The statistically significant SNP within ROCK2 was found to be of strengthened 
significance in the larger dataset, showing improved numerical p-value (by 
approximately 50 %) and relative significance to the other SNPs tested. In the initial 
dataset OAR3_21684794.1 was ranked equal 200
th
 of 366 SNPs (<0.05; placing it in the 





 of 411 SNPs (<0.05; placing in the top ~30 % of significant SNPs). Given 
the limitations of the analyses, the exploratory nature of the investigation and a p-value 
of 0.02278 (Table 3.9) this was taken as evidence for the potential involvement of this 
region with OCPMD. 
 
Table 3.8. Association analysis results of SNPs within the ROCK2 gene in the final dataset.  






Chi2 df p-value 
3 OAR3_21684794.1     A G Recessive 14/0  4/2 5.185 1 0.02278 
3 OAR3_21630699.1     A G Allelic 0/28 4/8 10.37 1 0.001281 
 
3.2.3. Linkage Analysis 
Linkage analysis was conducted on the SNP genotypes of the available flock 
members to determine regions of the genome which may show evidence of linkage to 
the disease state, using the program Merlin as described in Section 2.3.1.3.  
Linkage analysis yielded a maximum LOD score of only 0.66, and a minimum p-
value for this of 0.04. There were 1614 SNPs which had a LOD of 0.66 and p-value of 
0.04. Because of this, the linkage analysis was deemed to be too uninformative (there 
weren’t enough complete nuclear family groups) to alone convincingly indicate possible 
target genes for further investigation, and was thus only used as additional evidence for 
or against any potential targets.  
 
The analysis of SNPs within a region of chromosome 3, which included ROCK2, 
yielded the following results: 
 
Table 3.9. Linkage analysis for SNPs within the ROCK2-containing homozygous region 
SNP LOD p-value 
s04366.1 0.54 0.06 
s43586.1  0.53 0.06     
s44598.1  0.51 0.06     
s62248.1  0.51 0.06     
s39730.1  0.50 0.06     
OAR3_21684794.1 0.48 0.07     
OAR3_21630699.1  0.50 0.07 
OAR3_21695741.1 0.47 0.07 
 
While none of these SNPs reached the maximum LOD score possible for the 
dataset, the positive LOD scores in the region surrounding ROCK2 provided supporting 
evidence for potential involvement of the gene with the disease, and thus further 
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supports it as our prime candidate, especially in view of negative LOD scores for many 
other candidates in consideration. 
3.2.4. Whole-genome sequencing 
The whole-genome sequencing data provided by Dr. James Kijas was originally 
intended to be used for discovery, but on inspection found to be of too low coverage 
(8x) to provide sufficient information for this purpose, having been sequenced for 
assembly purposes. For use in a project like this one the coverage would ideally be 
~100x and so this line of investigation was abandoned in favour of the other 
approaches. 
3.2.5. Candidate Geneset 
The candidate geneset for biological investigation comprised the candidates selected 
from homozygosity mapping and the association analysis, with any genes of potential 
interest also examined in regards to the results of linkage analysis.  
Of the three SNPs occurring within the ROCK2 gene, one was able to be tested 
under the recessive model. One was not able to be tested under the recessive model due 
to a lack of divergent SNP genotypes, but was able to be tested under an allelic model, 
and results were suggestive of a significant effect (Table 3.8). The remaining SNP was 
of the same genotype for all individuals in the sample group and thus could not be 
tested. 
3.2.6. Biological plausibility investigation 
Between 50 and 100 genes were chosen for further investigation based on evidence 
from homozygosity mapping, association analysis, and supported by linkage analysis. 
The best candidate was concluded to be ROCK2. 
ROCK2 is a rho-associated kinase, the predominant ROCK isoform in skeletal 
muscle. Rho-dependent kinases like ROCK2 are major downstream effectors of RhoA, 
important in regulating myogenesis, however the specific functions of the ROCK 
isoforms are not currently well defined. It is progressively upregulated during myoblast 
differentiation, and an isoform of ROCK2, ROCK2m, has been shown to be 
preferentially expressed in skeletal muscle. This isoform is generated by alternative 
splicing of an evolutionarily conserved intron occurring between exons 27 and 28, 
called 27’ (Pelosi et al., 2007). Rock2m was demonstrated to be common to human, rat 
and mouse genomes and is heavily upregulated during myogenic differentiation (Pelosi 
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et al., 2007). This information suggests that a mutation within this intron, 
downregulating expression of the Rock2m isoform or changing the protein product, 
could result in a skeletal muscle-specific pathology.  
3.3. Molecular Biological Investigations of Prime Candidate Gene 
The best candidate chosen from bioinformatics analyses, ROCK2, was investigated 
in the laboratory using molecular biological techniques. The goal of this work was to 
sequence the cDNA from an affected and carrier sheep, in pursuit of identifying a 
putative disease-causing variant that was homozygous in the affected and heterozygous 
in the carrier. The region around and including the ROCK2m isoform-specific intron, 
27’, was considered to be the most likely location of such a mutation. 
3.3.1. RNA Extraction 
RNA was extracted from skeletal muscle tissue of an affected (#398) and a carrier 
(#1563) sheep of the OCPMD flock in order to synthesise cDNA for subsequent PCR 
amplification and sequencing for analysis. The muscles with the most pathology in the 
affected individuals (e.g. soleus) were unlikely to provide sufficient muscle tissue for 
analysis (as they had turned to fat) so a muscle not normally affected (gracilus) was 
chosen for RNA extraction. In the carrier, an RNA extraction was carried out for both 
the gracilus and the soleus. A second elution was performed though the RNA columns 
to ensure all RNA was recovered. 
Table 3.10. RNA extraction concentrations from skeletal muscle tissue. 
Tissue Elute RNA conc. (ng/L) Absorbance 
260/280* 
398 Gracilus 1 29.55 1.84 
2 20.00 1.815 
1563 Gracilus 1 219.8 1.98 
2 52.95 1.96 
1563 Soleus 1 82.4 2.045 
2 20.1 1.98 
 
RNA was successfully extracted from all tissues. The extraction from the affected 
skeletal tissue was of considerably lower concentration than the other samples, and the 
absorbance ratio at 260/280 nm indicated a less pure sample, however it was still 
considered to be of reasonable quality after checking it by gel electrophoresis and 
primer amplification. The extractions from the carrier gracilus and soleus were of higher 
quality and quantity. 
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3.3.2. cDNA Synthesis, PCR Amplification & Electrophoresis 
cDNA was synthesized from the affected and carrier RNA samples. PCR 
amplification of each primer pair was attempted using each of the cDNA samples and 
the product purity and size confirmed by electrophoresis. 
 
Figure 3.1. Electrophoresis of PCR products from ROCK2 primer pairs. Gel columns are numbered 
sequentially from 1, left to right. Affected gracilus is referred to as (1) carrier gracilus as (2) and carrier soleus 
as (3), while the amplifications of control human skeletal muscle are (4) and (5).  PCR products as follows:  
Gel A. 1: 100 bp ladder; 5: 1B; 6: 2B; 7: 3B; 8: H2O; 9: 1A; 10: 2A; 11: 3A; 12: H2O. Gel B. 1: 1C; 2: 2C;  
3: 100 bp ladder; 4: H2O. Gel C. 1: H2O 2: 1D 3: 2D  4: 100 bp ladder 5: 3D  Gel D. 1: 100 bp ladder 2: 1E  3: 
2E  4: 3E  5: H2O  Gel E. 1: 3F 2: 5F  3: H2O  4: 100 bp ladder  Gel F. 1: 2H 2: 3H  3: H2O  4: 100 bp ladder  
5: 4H 6: 5H. Gel G. 1: 100 bp ladder 2: 3C Gel H. 1: 1F 2: 1FQ 3: 5F 4: H2O 5: 100 bp ladder 
    





Gel electrophoresis showed expected product sizes (Table 3.11.) for most primer 
sets amplified through PCR. While the carrier gracilus cDNA did not have a clear gel 
Primer Set A B C D E F G H 
Affected 
gracilus 
      X  
Carrier 
gracilus 
      X  
Carrier 
soleus 
      X  
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image for its PCR product for fragment F its subsequent sequencing demonstrated its 
successful amplification. 
3.3.3. Sequencing 
Sequencing of most ROCK2 primer sets was successfully carried out and aligned to 
the bovine cDNA as reference, due to the unavailability of the ovine ROCK2 cDNA 
sequence. 
Table 3.12. PCR products that were successfully sequenced and aligned to the bovine ROCK2 cDNA reference. 
Primer Set A B C D E F G H 
Direction F R F R F R F R F R F R F R F R 
Affected 
gracilus 
                
Carrier 
gracilus 
                
Carrier 
soleus 
                
 
Primer sets which covered the termini of ROCK2 were not able to be successfully 
amplified or the resulting PCR products sequenced and, while the electrophoresis of D, 
E and F primer sets for the affected indicated a PCR product of the expected sizes, these 
were not able to be successfully sequenced and aligned to the bovine cDNA. 
The total size of the bovine ROCK2 cDNA is 4101 bp and this sequence was chosen 
to be the reference sequence upon which to attempt to align the sequencing results from 
the PCR products derived from the ovine cDNA samples. After quality control based on 
examination of the individual chromatograms for each sequencing result, there were 36 
differences between the consensus ovine sequence results and 3920 bp of the bovine 
cDNA sequence covered, some of these resulting in amino acid changes. 
Of note, the forward strand sequences for primer set F for both the carrier gracilus 
and soleus appeared to mismatch with the bovine cDNA sequence, but have 100% 
agreement with one another. The sequences of the reverse strand were in near perfect 
agreement with the bovine cDNA reference, however. It was determined that these PCR 
products included a transcript that contained an additional 171 bp to the bovine cDNA 
reference sequence. When comparing these nucleotides to that of the bovine genomic 
sequencing for ROCK2, the 171 bp (equating to 57 amino acids), represent the inclusion 
of a section of intron 27 of the gene, relating to the muscle-specific exon in the 
ROCK2m transcript.  The bovine and ovine sequences for these 171 bp is identical, with 
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there being 8 nucleotides different between the bovine/ovine and human cDNA 
sequences for this region. 
Of the regions that were covered by sequencing of good quality, there were no 
obvious variants that were homozygous in the affected and heterozygous in the carrier, 
indicative of a disease-causing variant, e.g. a mutation. 
Figure 3.2. Snapshot of the sequencing chromatogram of a segment of fragment F highlighting the beginning 
of the variable region of the ROCK2 transcript. 
 
There is a drop in relative intensity of the chromatogram peaks at the approximate 
start of the putative 27’ (indicated by the vertical line). There is also an increase in 





4. Discussion and Future Directions 
This work has identified a prime candidate gene, ROCK2, which may contain the 
causative mutation of OCPMD. Further, it has additionally successfully sequenced 
much of the cDNA for ROCK2 and identified a novel alternative transcript comparable 
to ROCK2m, previously only reported in humans, mice and rats. This is the first 
evidence for the existence of ROCK2m in sheep, the transcript resulting from the 
inclusion of an additional exon (27’) derived from a conserved intronic region between 
exons 27 and 28 being spliced into the transcript. Additionally, this work has set the 
stage for the complete sequencing of this transcript in the OCPMD flock in search of the 
putative disease-causing mutation. 
Despite substantial past efforts over the past two decades towards revealing the 
genetic cause of OCPMD, traditional methods of investigation were unsuccessful. The 
major hurdles obstructing these investigations, such as an incomplete and thus poorly-
annotated sheep genome, have been mostly overcome. The advent of SNP arrays, 
second-generation sequencing and the work of the ISGC, along with advancements in 
bioinformatics tools and techniques, have provided the best opportunity yet to discover 
the causative disease gene, despite the continued existence of some limitations. The 
collaboration with Dr. James Kijas at CSIRO has provided a conduit to the ISGC and a 
means by which SNP genotype and whole-genome sequencing data could be obtained. 
Another boon to this research was the birth, in 2012, of 4 sibling lambs affected by 
OCPMD, through in vitro fertilisation techniques. The inclusion of their genetic 
material into the analyses added greatly to their informativeness. 
Bioinformatics analyses, comprising three separate lines of investigation, pointed 
towards ROCK2 as a plausible candidate for a causative mutation in the OCPMD flock. 
While some other candidates were of greater statistical significance in one particular 
approach, none besides ROCK2 was implicated by all three.  
Using the homozygosity mapping as the starting point for our analyses overcame 
many of the problems associated with the small dataset, as this data filtering process 
was not subject to statistical assumptions. Of all genes within regions implicated by 
homozygosity mapping, only the region containing ROCK2 contained SNPs which met 
the nominal 0.05 significance level in association analysis. Additionally, these SNPs 
were found in linkage analysis to have positive LOD scores associated with them, 
further implicating ROCK2. As with the ROCK2-containing homozygous region, the 
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next most interesting candidate gene from homozygosity mapping, JMJD1C, shared its 
‘background homozygosity’ (that of the SNPs) with 2 of 6 carriers. For these 
homozygous SNPs, however, linkage analysis provided negative LOD scores, and none 
of these SNPs achieved significance in the association analysis. 
In the case of the ROCK2-containing region, the SNP genotyping for one of carriers 
homozygous for the run of SNP homozygosity (#1563) has some possible issues of data 
quality, as there were a large number of Mendelian inheritance errors reported due to 
‘impossible recombination patterns’ registered during linkage analysis. In addition, both 
carriers who shared this background homozygosity were bred from the same sire, a 
normal individual from outside of the pedigree, which may have resulted in a 
background SNP haplotype the same as that of the affected individuals without the 
putative causative mutation (it may have arisen only relatively recently on the same 
background haplotype). 
In the case of the JMJD1C-containing region, there is no explanation yet for this 
sharing of ‘background homozygosity’ with the affected individuals.  As mentioned 
previously however, the sharing of background homozygosity with carriers of the flock 
was not alone considered sufficient evidence to disqualify the genes within a region of 
homozygosity in the affected individuals from investigation. 
  The association analysis resulted in over 300 SNPs which met the criteria for 
inclusion in the candidate gene set, and the genes within which these were located (or 
were physically close to) were further investigated. The 158 SNPs of the ‘overlap set’, 
in becoming more significant in the final analysis, were (ranked) higher up our list of 
potentials, as were the genes within which were located any of the 100 most highly 
significant SNPs by p-value, and any genes in which multiple SNPs achieved statistical 
significance. The allele distribution was also taken into consideration (as the ‘control’ 
sheep in the analysis were all known carriers), as was the fact that a significant SNP 
might not itself be the causative mutation, but instead simply be in strong LD with the 
variant. It was considered that in this discovery-based research project it was greater 
importance to cast a wider net, as there is no replication dataset or ‘gold standard’ for 
comparison analysis (e.g. no dbSNP for sheep). The situation is akin to that of the 
1990’s for researchers studying human diseases. In the case of replication of previous 
work or two independent datasets, more stringent cutoffs would have been employed.  
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While many hurdles and challenges were overcome to make this work possible, 
additional remained that limited or restricted some of the bioinformatics analyses. 
Without the valuable contributions of Dr. James Kijas in performing the whole-genome 
sequencing and SNP genotyping it would not have been possible to conduct the 
homozygosity mapping, association analysis or linkage analysis for this project. 
However, due to the limited reagents for the SNP array still available (the SNP array 
has been discontinued) only a subset of the sheep for which we had biological samples 
available were able to be SNP genotyped and thus the pedigrees were not as informative 
(complete) as would ideally be possible. In addition, the lack of a SNP database beyond 
the SNP array, HapMap sheep equivalent (or Merino-specific database), dbSNP for 
sheep, or well defined reference genome made accounting for any larger population-
based background genetics difficult.  
The association analysis was inhibited by a smaller sample size than would have 
been ideal, and a true GWAS would have required SNP genotyping of much finer detail 
genome coverage, though this will be possible in the future as the sheep genome project 
matures. The fact that the tests did not meet the criteria for independence and small 
number of individuals prevented traditional control for multiple testing, as many of the 
multiple-testing correction methods are for independent samples (Gao et al., 2010), 
however this was overcome by using our complementary, overlapping analysis 
approaches. 
The linkage analysis was limited by not only the complexity of the pedigree 
(creating computational hurdles with large memory requirements) but also by the 
limitations on which individuals were able to be SNP genotyped. This resulted in a 
pedigree for which the large majority of individuals genotyped were not connected into 
nuclear families (integral to map inheritance through linkage analysis), thus reducing 
the informativeness and power of the dataset. This led to significant time being 
expended fruitlessly and a number of strategies being attempted and discarded. These 
included the use of alternate tools such as LAMP (Li et al., 2005) and strategies to 
maximise potential results, including carrying out chromosome-specific linkage 
analysis, prior to the additional genotyping of connected individuals (#398, #30, RED 
#1 - RED #4) allowing the use of Merlin to conduct a limited linkage analysis. This 
analysis was most likely underpowered, as evidenced by the distribution of LOD scores 




Despite some of the limitations, it was reassuring that the prime candidate chosen 
for follow up, ROCK2, was supported by all lines of investigation; homozygosity 
mapping, association analysis, and linkage analysis. It was additionally considered 
through interrogation of the literature to represent a biologically relevant and plausible 
candidate for involvement in the OCPMD phenotype. 
Implications 
Skeletal muscles are essential for the functions of daily life; required for breathing, 
movement, swallowing and walking. As outlined in the introduction, skeletal muscle 
fibres can be classified into slow twitch or fast twitch, with different muscles in the 
body comprised of varying proportions, based on their functions. 
As discussed in Section 1.4., diseases of skeletal and cardiac muscles can be 
emotionally, socially and economically devastating. Some muscle diseases are lethal 
before or shortly after birth. Progressive diseases like OCPMD have a daily impact and 
disable patients over a lifetime. Unfortunately for patients and their families, very little 
in the way of treatments are available, although supportive measures such as ventilators 
and wheelchairs can mitigate the impact of symptoms. 
While the first step to rationally devising therapeutic approaches for a disease is 
information of the genetic causes, identification of the disease gene is not always 
sufficient in itself to design possible treatments. It is crucial to understand how the 
mutated gene leads to disease at the DNA, RNA and/or protein levels and through to the 
pathobiology of the disease. This can be a complex problem to solve, and one of the 
best ways to resolve this complexity is through animal models (Abresch et al., 1998). 
Moreover, an animal model is often essentially required as a test-bed for evaluating 
potential therapies. 
Rather than generating a new mouse, zebrafish or Drosophila animal model (the 
more typical laboratory animal for genetic studies) of a particular human genetic muscle 
disease, this project has played a vital role in revealing the likely genetic cause of an 
existing, internationally unique, sheep model of a muscle disease. This is similar in 
approach to projects that phenotype mice subjected to ENU mutagenesis and 
subsequently attempt to identify the causative mutation in phenotypically interesting 
results (Fossett et al., 1990). The advantage of this project is that we have already 
identified the OCPMD flock as of major phenotypic importance in regards to human 
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disease and know that the mutation is naturally occurring in the pedigree, suggesting 
that it could well have an analogue in humans. 
For decades, this Western Australian sheep model has been considered of high value 
to the medical research community, in that the exhibited pathologies in skeletal muscles 
of affected sheep overlap with different human skeletal muscle diseases, as discussed in 
Section 1.6.1. Additionally, the selective nature of slow fibre-predominant muscles 
being affected is reminiscent of some human skeletal muscle diseases such as 
McArdle’s disease (Miteff et al., 2011). Lastly, the size of sheep, along with their 
skeletal muscle fibre-predominance and distribution is comparable to humans, 
especially in contrast with most existing animal models of muscle disease, such as mice. 
One of the biggest hurdles in potential treatment for disorders affecting the skeletal 
muscles is delivery to the target cells (Fairclough et al., 2013). Thus, if a potential 
therapy were to be trialled in the OCPMD sheep and found to be successful, it might be 
presumed that this therapy would have a greater chance of being effectively translated 
to humans as opposed to a treatment proven in mice. 
ROCK2 is the predominant predominant ROCK isoform expressed in the skeletal 
muscles which, from first principles, must be the case in any gene causing a skeletal 
muscle-specific pathology (Pelosi et al., 2007). ROCK2 is a downstream effector of 
Rho, which has been implicated in the control of skeletal muscle differentiation 
(Doherty et al., 2011). Not supporting this hypothesis, however, was the fact that the 
major isoform of ROCK2 is also expressed in a range of other tissues, such as the heart, 
lung and brain, none of which are affected in OCPMD (Pelosi et al., 2007, discussed in 
Section 1.5.3). The discovery of a ROCK2 isoform, ROCK2m, which is preferentially 
expressed in the skeletal muscles and heavily upregulated during myogenic 
differentiation, provided a possible mechanism by which a mutation in ROCK2 could 
result in a pathology limited to skeletal muscles (Pelosi, et al., 2007). However, for 
completeness, the whole cDNA sequence was attempted to be sequenced in the skeletal 
muscles from both the carrier and affected sheep as it was also possible that a variant 
elsewhere in the gene could be disease-causing and produce exclusively a muscle 
phenotype.  For example, a missense variant might exist in exon 3 of ROCK2, and 
produce an amino acid change in all transcripts. If this amino acid is involved in binding 
another protein that is only present in skeletal muscle, then such a conversion may only 
have consequence in skeletal muscle. 
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As described earlier, ROCK2m is an alternative isoform of ROCK2 which is 
expressed preferentially in the skeletal muscle tissues. Previously demonstrated only in 
humans, mice and rats, ROCK2m is differentiated from the major ROCK2 isoform by 
inclusion of a highly evolutionarily conserved intronic region. This is located between 
exons 27 and 28, and dubbed 27’ (Pelosi et al., 2007). In mice, 27’ is 171 bp and its 
inclusion in ROCK2m results in a transcript 57 amino acids longer than the major 
isoform. Thus it became of biological plausibility that a variant within this 171 bp 
region, a deletion within or encompassing it, or a change affecting the splicing of 27’ or 
ROCK2m, could result in a skeletal muscle-specific phenotype.  
In designing a method for screening ROCK2 for a potentially causative variant, it 
would have been ideal to target 27’ directly. Unfortunately, due to the incompleteness 
of the ovine reference genome, and the low level of coverage (8x on average) afforded 
by the whole-genome sequencing of #398 and #1560, it was not possible to design 
primers to target genomic DNA in the surrounding regions of 27’. Despite the highly 
evolutionarily conserved nature of the 27’ sequence in mice, humans and rats, the 
flanking nucleotides were not, making primer design for ovine genomic DNA from the 
sequences of other species difficult and unlikely to be successful. In addition, the 
amplification and sequencing of 27’ alone would have ignored the possibility of a 
causative variant within the major ROCK2 isoform; the muscle specificity related to a 
specific binding partner present in affected tissues.  
ROCK2 in sheep is 140,764 bp long. The coding regions of ROCK2 were found to 
be highly conserved across mammalian species, but the introns were not. This, 
combined with the limitations of the sheep reference genome, suggested that to design 
primers based on the genomic DNA flanking exons would be unlikely to find success. 
The lack of a published sheep ROCK2 cDNA sequence and conservation of coding 
regions across species, in combination with the relatively large number of exons (32) 
spanning approximately 4 kbp, suggested that the most viable strategy would be primer 
design based on highly conserved regions in human, mouse and bovine cDNA 
sequences in order to sequence the entirety of the ROCK2 cDNA. Therefore, we 
decided that this was best accomplished by the amplification and sequencing of the 
cDNA in overlapping fragments rather than amplifying and sequencing each exon from 
genomic DNA individually. 
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The presence of 27’ and ROCK2m was demonstrated in humans and mice 
previously, and the bovine genome is the closest to that of sheep published. Thus these 
three cDNA sequences were chosen for primer design. These were aligned and primers 
designed in overlapping pairs based on regions of 100% of near-100% identity. Eight 
primer pairs were created so as to produce overlapping fragments encompassing the 
entirety of the ROCK2 cDNA sequence. While it would have been preferable to have 
designed a forward primer in the 5’ UTR of the cDNA sequence rather than the start 
codon, the 5’ UTR sequence was not available for the bovine ROCK2 cDNA sequence, 
and that of the human and mouse ROCK2 cDNA showed variability between one 
another, indicating that a primer designed for the ovine 5’ UTR would be unlikely to 
find success. Because of this limitation, it is probable that a disease-causing variant in 
the first 15 nucleotides of ROCK2 would not be identified by my analyses as, for these 
bases, the sequence of the primer would be observed in the sequencing results, rather 
than that of the cDNA. 
Each cDNA sample created from the extracted skeletal muscle RNA was 
successfully amplified by multiple primer pairs, indicating that the extracted RNA was 
of sufficient quality, and the cDNA synthesis efficacious.  Fragment G was the only 
fragment not able to be amplified from any cDNA sample, possibly due to the less than 
optimal temperature difference (of ~10 
o
C) between the forward and reverse pair; this 
was an unfortunate necessity as the 5’ region of the cDNA sequence for ROCK2 was 
extremely GC-rich, raising the required temperature for denaturation. This may be 
overcome in later work by designing a paired reverse primer in a similarly GC-rich 
region, although there are well reported problems with GC-rich primer amplification 
also (Frey et al., 2008). Another possible strategy may be to attempt amplification using 
the genomic DNA sequence available in the reference genome, now that the sequence of 
the ovine cDNA for the 3’ region from this target area can be identified.  
Fragment F was not able to be sequenced in the affected individual, despite an 
apparent product observed from electrophoresis. While this was unfortunate, if the 
disease is caused by a deletion in 27’, the ROCK2m transcript may not be present in the 
affected individual, and the presence of a homozygous mutant transcript in muscle not 
normally affected by the pathology is perhaps unlikely. The muscle wasting in the 
affected individual prevented the use of a ‘normally affected’ muscle for RNA 
extraction, though this could potentially be overcome by excising soleus tissue from a 
younger affected individual (e.g. RED 1 – 4) as this muscle wasting is progressive over 
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the life of the sheep. The more important finding is to determine whether there is a 
heterozygous mutation in the carrier sequence, as a ‘normally affected’ muscle in the 
carrier would express ROCK2m, but possess a heterozygous mutation. 
Fragment H was not able to be amplified from the affected gracilus cDNA. A 
possible cause for this failure is that the affected gracilus cDNA is not amplifying for 
fragment H as there is a deletion under one or both of the primer locations, and this 
could quite plausibly be the genetic cause of the disease. As an affected individual is 
predicted to be homozygous for the causative mutation, whereas a carrier only 
heterozygous, one would expect the absence of PCR product for the “affected” cDNA 
but the presence of a product from a “carrier” cDNA. Sequencing for fragment H was 
unsuccessful for both the carrier gracilus and the carrier soleus, despite relatively clear 
banding for each (Fig. 3.1.). This may be the result of the additional unclear bands being 
indicative of both transcripts being present, the major isoform of ROCK2, and 
ROCK2m, thus interfering with the sequencing results. A possible solution may be to 
excise the larger product bands from a gel, purify, and sequence this, or to clone a 
mixed pool of products and sequence individual clones, as each clone would only 
contain one or other fragment. Amplification of these fragments from cDNA will be 
further attempted in continued studies. 
Fragments F and H would encompass the predicted location of 27’ in sheep, 
spanning exons 24 – 32 and exons 24 – 3’ UTR, respectively. Unfortunately the PCR 
products for segement H did not sequence well and due to the limitations of time these 
experiments could not be repeated to include in this thesis work. However, the 
successful sequencing of fragment F using the forward primer from the carrier soleus 
and gracilus in this work demonstrated the presence in the OCPMD sheep of a region 
analogous to 27’, this being of 171 bp, distinctly different from the reference sequence 
and that of both reverse strands (which were in agreement with the reference) Further, 
the bases towards the end of the reverse sequencing showed agreement with that of the 
putative 27’ at an equivalent position as shown in the forward strand sequence. 
Additionally, a drop in the intensity of chromatogram peaks at approximately the start 
of this region (Fig. 3.2.) indicated that the region contained two products. This 
identification has enabled the design of primers specific to 27’, which will allow the 
sequencing of this region in not only the carriers but also, we expect, in the affected 
individuals of the OCPMD flock. At this stage we have successfully sequenced ~90% of 
the ROCK2 cDNA in the carrier, and ~80% of the sequence in the affected. 
76 
 
Discovering a variant within 27’ which is homozygous within the affected and 
heterozygous within the carrier will provide very strong evidence for the involvement of 
ROCK2m with this unique disease pathology. Rho kinases like ROCK2 have been 
reported to be potential therapeutic targets in the treatment of cardiovascular disease 
(Surma et al., 2011), but ROCK2 has never before been implicated in causing any 
disease, let alone one of skeletal muscle. If proven through additional work as being the 
disease gene this will provide the possibility of widening the genetic screening net, and 
assisting in the characterisation of human disease which has not yet had its genetic 
cause determined, such as the phenotypically similar LGMD2G (Paim et al., 2013). If a 
rare human disease like LGMD2G is able to be linked to this gene, the ovine muscular 
dystrophy model will additionally provide a valuable opportunity to study the 
pathogenesis in a way not possible in a human population. 
This project has identified the most likely location for a variant causative of the 
OCPMD pathology. Primers enabling closer interrogation of sheep 27’ have been 
designed based on the sequencing results of this project and this sequencing will be 
subsequently undertaken. If a potentially causative variant is identified, replication will 
be undertaken using the already collected biological samples from a large number of 
individuals of the flock. The strategies outlined above will be used to amplify and 
sequence the remaining fragments which were unsuccessful in this work. In the absence 
of a heterozygous variant being identified in the fully sequenced cDNA of ROCK2, the 
genomic DNA of ROCK2 may be sequenced using either traditional (Sanger) or next-
generation techniques. A mutation in the promoter region upstream of ROCK2 may also 
affect ROCK2 or ROCK2m expression, and this could be investigated using quantitative 
RT-PCR. 
In addition, the authors of the 2007 paper (Pelosi et al., 2007) providing first 
evidence of the existence of 27’, and ROCK2m, have been contacted in search of the 
novel antibodies they developed for the isoform. If this is able to be secured it will 
provide the ability to carry out histochemical analysis to examine differential expression 
between carriers and affected sheep of the flock. Even in the absence of this antibody, 
western blotting using a generic ROCK2 antibody may provide a valuable avenue of 
approach. 
The ratio of the transcripts of ROCK2 to ROCK2m in skeletal muscles was reported 
to vary between muscles in mice (Pelosi et al., 2007). By quantitatively amplifying the 
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ROCK2m fragment in different muscles we may be able to determine whether the 
muscles exhibiting pathology in the OCPMD flock are those which have a greater 
proportion of ROCK2m. The specificity of ROCK2m to type I fibres in comparison to 
type II has not been previously examined, and the combination of ROCK2m-
immunostaining along with myosin heavy chain antibodies to detect different myofiber 
types may provide additional evidence for or against this as a disease gene candidate. 
If all of these investigations return negative evidence for ROCK2 involvement in the 
OCPMD pathology, we may investigate the next most significant candidate from our 




This ambitious, multi-disciplinary project combining both in silico and molecular 
techniques has identified a prime candidate gene for a causative genetic variant in the 
OCPMD flock. It has additionally provided the first evidence of ROCK2m in sheep and 
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Appendix I: Homozygsity Mapping Results 
Initial Dataset 
Affected individuals. 5 minimum sequential homozygous SNPs 
 
Length Chrom   Marker (SNP name, position, nearest gene, genotypes for affecteds) 
8 3  s04366.1(19896460)(no gene)[ GG GG GG GG GG GG GG GG GG] 
 s43586.1(19945849)(no gene)[ GG GG GG GG GG GG GG GG GG] 
 s44598.1(19989596)(no gene)[ GG GG GG GG GG GG GG GG GG] 
 s62248.1(20012335)(no gene)[ AA AA AA AA AA AA AA AA AA] 
 s39730.1(20027673)(Name=Uncharacterized)[ GG GG GG GG GG GG GG GG GG] 
 OAR3_21630699.1(20052991)(Name=PQLC3)[ GG GG GG GG GG GG GG GG GG] 
 OAR3_21684794.1(20105333)(Name=ROCK2)[ AA AA AA AA AA AA AA AA AA] 
 OAR3_21695741.1(20116222)(Name=ROCK2)[ GG GG GG GG GG GG GG GG GG] 
 
6 25  OAR25_19823535.1(19167503)(Name=NRBF2)[ GG GG GG GG GG GG GG GG GG] 
OAR25_19926183.1(19270565)(Name=JMJD1C)[ GG GG GG GG GG GG GG GG GG] 
OAR25_19941944.1(19286373)(Name=JMJD1C)[ GG GG GG GG GG GG GG GG GG] 
OAR25_20026839.1(19369540)(Name=JMJD1C)[ GG GG GG GG GG GG GG GG GG]     
OAR25_20041897.1(19386582)(Name=JMJD1C)[ AA AA AA AA AA AA AA AA AA] 
OAR25_20106030.1(19438048)(Name=JMJD1C)[ AA AA AA AA AA AA AA AA AA] 
 
5 13  OAR13_60759835.1(55866953)(Name=CDH26)[ AA AA AA AA AA AA AA AA AA] 
 s47781.1(55915765)(no gene)[ AA AA AA AA AA AA AA AA AA] 
 OAR13_60821868.1(55934178)(no gene)[ AA AA AA AA AA AA AA AA AA] 
 OAR13_60855392.1(55970160)(Name=SYCP2)[ AA AA AA AA AA AA AA AA AA] 
 OAR13_60893851.1(56010691)(no gene)[ AA AA AA AA AA AA AA AA AA] 
 
5 11  s44351.1(49904840)(Name=CCDC57)[ AA AA AA AA AA AA AA AA AA] 
 s30936.1(49940471)(Name=FASN)[ GG GG GG GG GG GG GG GG GG] 
 s08804.1(49987461)(no gene)[ GG GG GG GG GG GG GG GG GG] 
 s49850.1(50004896)(no gene)[ AA AA AA AA AA AA AA AA AA] 
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 OAR11_53396507.1(50045164)(Name=LRRC45)[ GG GG GG GG GG GG GG GG GG] 
 
Carrier Individuals. 5 minimum sequential homozygous SNPs 
 
9 18  OAR18_57753977.1(53977812)(Name=TGM5)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s59424.1(53988694)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR18_57812263.1(54039497)(Name=TGM7)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR18_57822087.1(54047823)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00]    
 s08497.1(54126281)(Name=TP53BP1)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 s65227.1(54133053)(Name=TP53BP1)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00]  
 OAR18_57945473.1(54174325)(Name=TP53BP1)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00]  
 s47566.1(54226355)(Name=MAP1B)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 DU404011_458.1(54252674)(Name=PPIP5K1)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 
8 8  OAR8_18721587.1(16842172)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 OAR8_18751992.1(16866718)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR8_18770427.1(16882313)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR8_18777471.1(16888761)(Name=BROMI)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 OAR8_18857269.1(16930039)(Name=BROMI)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 OAR8_18904554.1(16975578)(Name=BROMI)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR8_18948860.1(17014826)(Name=BROMI)[ 00 00 CA CA 00 00 00 00 CA CA CA 00 00] 
 OAR8_18997620.1(17052479)(Name=BROMI)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 
7 5  s02334.1(14617884)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s57684.1(14686309)(Name=ANGPTL4)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s17355.1(14712996)(Name=RAB11B)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 OAR5_16996550.1(14775024)(Name=HNRNPM)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 s15525.1(14792565)(Name=PRAM1)[ 00 00 AC AC 00 00 00 00 AC AC AC 00 00] 
 OAR5_17075528.1(14847585)(Name=ADAMTS10)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 OAR5_17102793.1(14879240)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 
6 18  OAR18_33701857.1(32280143)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR18_33752500.1(32330978)(Name=SIN3A)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR18_33774245.1(32352543)(Name=SIN3A)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR18_33835260.1(32409159)(Name=COMMD4)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 s08407.1(32452463)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
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 OAR18_33902994.1(32479250)(no gene)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 
6 14  OAR14_3404872.1(3486435)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
   s23868.1(3609268)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR14_3688132.1(3712183)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s10865.1(3782575)(no gene)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 s57571.1(3800340)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s30966.1(3813758)(no gene)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 
6 9  OAR9_75040566.1(70840453)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR9_75075388.1(70876514)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR9_75093968.1(70895159)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s38039.1(70925830)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR9_75230004.1(70959064)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 OAR9_75289690.1(71053054)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 
6 1  OAR1_103393742.1(96909929)(Name=PDE4DIP)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR1_103420822.1(96934926)(Name=PDE4DIP)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 OAR1_103445194.1(96960192)(Name=PDE4DIP)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 OAR1_103547224.1(97033682)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR1_103772253.1(97192711)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR1_103790218.1(97209577)(Name=FMO5)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 
5 23  OARX_125130516.1(100425156)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OARX_125084587.1(100474082)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OARX_125057668.1(100514641)(no gene)[ 00 00 00 AA 00 00 00 00 AA AA AA 00 00] 
 OARX_125044988.1(100528609)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OARX_125031440.1(100546822)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 
5 18  OAR18_31865428.1(30609238)(no gene)[ 00 00 CA CA 00 00 00 00 CA CA CA 00 00] 
 s04966.1(30658559)(Name=SCAPER)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR18_31946902.1(30682003)(Name=SCAPER)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR18_31974215.1(30706077)(Name=SCAPER)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 s40729.1(30783420)(Name=SCAPER)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 
5 18  s24856.1(8815383)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
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 OAR18_8693731.1(8913593)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR18_8733617.1(8953384)(Name=Uncharacterized)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 OAR18_8785465.1(9005514)(no gene)[ 00 00 00 AA 00 00 00 00 AA AA AA 00 00] 
 OAR18_9078383.1(9031682)(no gene)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 
5 18  s40731.1(59640699)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s10572.1(59668774)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 OAR18_63721952.1(59706427)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s36630.1(59743824)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s50855.1(59799782)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 
5 17  OAR17_28218413_X.1(25672666)(no gene)[ 00 00 GA 00 00 00 00 00 GA GA GA 00 00] 
 OAR17_28261838.1(25713704)(no gene)[ 00 00 AC AC 00 00 00 00 AC AC AC 00 00] 
 OAR17_28312619.1(25767191)(no gene)[ 00 00 AC AC 00 00 00 00 00 AC AC 00 00] 
 OAR17_28363294.1(25826660)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 OAR17_28390642.1(25862600)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 
5 16  OAR16_16777017.1(15134783)(Name=RNF180)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 OAR16_16801439.1(15159802)(Name=RNF180)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 OAR16_16902918.1(15280464)(Name=RNF180)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 OAR16_16928494.1(15306397)(Name=RNF180)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR16_16984728.1(15362234)(no gene)[ 00 00 00 AA 00 00 00 00 AA AA AA 00 00] 
 
5 16  OAR16_44680056.1(41134921)(Name=ZFR)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR16_44759148.1(41206143)(Name=MTMR12)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 OAR16_44812720.1(41229069)(Name=MTMR12)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s58356.1(41258135)(Name=MTMR12)[ 00 00 AA 00 00 00 00 00 AA AA AA 00 00] 
 OAR16_44884811.1(41295748)(no gene)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 
5 16  s45053.1(70559566)(Name=AHRR)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OARUn.54_510669.1(70664506)(Name=EXOC3)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s53565.1(70710282)(Name=SLC9A3)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s51002.1(70900966)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s37581.1(70922464)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 
5 14  s66108.1(34390195)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
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 OAR14_35908377.1(34477621)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s07117.1(34558103)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s65863.1(34566935)(Name=GFOD2)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 OAR14_36030253_X.1(34596131)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 
5 13  s63569.1(21664236)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR13_24163213.1(21673888)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR13_24206262.1(21688556)(no gene)[ 00 00 CC 00 00 00 00 00 CC CC CC 00 00] 
 s40227.1(21753962)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 s07619.1(21806857)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
5 13  s37974.1(15256050)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
s09489.1(15265028)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
OAR13_13397282.1(15307978)(Name=USP6NL)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
s23760.1(15359923)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
OAR13_13298202.1(15406880)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 
5 13  OAR13_60759835.1(55866953)(Name=CDH26)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s47781.1(55915765)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR13_60821868.1(55934178)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR13_60855392.1(55970160)(Name=SYCP2)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR13_60893851.1(56010691)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 
5 13  s67504.1(68158981)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 s10589.1(68213972)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 OAR13_73412719.1(68241391)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 OAR13_73486401.1(68306113)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 OAR13_73527165.1(68347344)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 
5 11  s35197.1(30193254)(Name=DNAH9)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s14669.1(30222632)(Name=ZNF18)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR11_32129276.1(30250362)(Name=MAP2K4)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR11_32155360.1(30275940)(Name=MAP2K4)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR11_32204952.1(30329562)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 
5 11  OAR11_61713996.1(57193316)(Name=SLC39A11)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
OAR11_61776871.1(57252925)(Name=Uncharacterized)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
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 s07746.1(57283705)(Name=SLC39A11)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s65471.1(57292356)(Name=SLC39A11)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s01777.1(57367601)(Name=SLC39A11)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 
5 9  s36433.1(88690261)(Name=CNGB3)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR9_94270944_X.1(88745479)(Name=CPNE3)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR9_94310472.1(88775547)(Name=CPNE3)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s70574.1(88836294)(Name=WWP1)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR9_94375693.1(88900878)(Name=WWP1)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 
5 9  s28418.1(80781440)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR9_85509697.1(80838913)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR9_85560833.1(80885666)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 OAR9_85594743.1(80924591)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR9_85619253.1(80947471)(no gene)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 
5 6  OAR6_28048390.1(24659269)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR6_28075131.1(24687510)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR6_28132840.1(24714766)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR6_28175615.1(24755360)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR6_28396848.1(24968246)(Name=Uncharacterized)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 
5 4  OAR4_31672384.1(30120791)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR4_31690929.1(30147111)(no gene)[ 00 00 00 00 00 00 00 00 AG AG AG 00 00] 
 OAR4_31727075.1(30179898)(no gene)[ 00 00 CA CA 00 00 00 00 CA CA CA 00 00] 
 s01678.1(30220570)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 OAR4_31796734.1(30244105)(Name=SP4)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 
5 3  OAR3_6854899.1(6774118)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR3_6897820.1(6820713)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR3_6950846.1(6871259)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s58010.1(6884511)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s13823.1(6989246)(Name=Uncharacterized)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 
5 3  OAR3_156362251.1(146504875)(Name=LRRK2)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR3_156409128.1(146552297)(Name=LRRK2)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
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 OAR3_156474166.1(146621605)(Name=LRRK2)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR3_156484814_X.1(146631986)(Name=LRRK2)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 OAR3_156555651.1(146703642)(Name=LRRK2)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 
5 3  s24023.1(60735953)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s51327.1(60804625)(Name=Uncharacterized)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 OAR3_64372580.1(60840244)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR3_64400364_X.1(60863772)(Name=UXS1)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR3_64436154.1(60899402)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 
5 2  s04563.1(248037266)(Name=RCC2)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s43889.1(248063253)(Name=PADI6)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 s08754.1(248069420)(Name=PADI6)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 s45037.1(248103245)(Name=PADI3)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR2_262394560.1(248130533)(Name=PADI3)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 
5 2  OAR2_77928516.1(73142522)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR2_77962229.1(73188664)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR2_78002934_X.1(73226330)(Name=KIAA1432)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 OAR2_78055691.1(73287723)(Name=KIAA1432)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR2_78106813.1(73333474)(Name=KIAA1432)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 
5 2  s47673.1(88986269)(no gene)[ 00 00 CC CC 00 00 00 00 CC 00 CC 00 00] 
 s40411.1(88992392)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00] 
 OAR2_95405699.1(89076235)(Name=Uncharacterized)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR2_95050543.1(89189237)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR2_95733865.1(89239384)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00] 
 
5 2  s47616.1(83090209)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR2_88340779.1(83115753)(no gene)[ 00 00 CA CA 00 00 00 00 CA CA CA 00 00] 
 s61655.1(83194854)(Name=TTC39B)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00] 
 OAR2_88441803.1(83214641)(Name=TTC39B)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 s23687.1(83305173)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 
5 1  s32216.1(128983286)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR1_139735768.1(129024743)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
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 OAR1_139783950.1(129072656)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00] 
 OAR1_140089069.1(129317012)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00] 
 OAR1_140104902.1(129332577)(no gene)[ 00 00 CA CA 00 00 00 00 CA CA CA 00 00] 
 
Final Dataset  
Affected Individuals. 5 minimum sequential homozygous SNPs 
Length Chrom   Marker (SNP name, position, nearest gene, genotypes for affecteds) 
 
6 3  s44598.1(19989596)(no gene)[ GG GG GG GG GG GG GG GG GG GG GG GG GG GG] 
 s62248.1(20012335)(no gene)[ AA AA AA AA AA AA AA AA AA AA AA AA AA AA] 
 s39730.1(20027673)(Name=Uncharacterized)[ GG GG GG GG GG GG GG GG GG GG GG GG GG GG] 
 OAR3_21630699.1(20052991)(Name=PQLC3)[ GG GG GG GG GG GG GG GG GG GG GG GG GG GG] 
 OAR3_21684794.1(20105333)(Name=ROCK2)[ AA AA AA AA AA AA AA AA AA AA AA AA AA AA] 
 OAR3_21695741.1(20116222)(Name=ROCK2)[ GG GG GG GG GG GG GG GG GG GG GG GG GG GG] 
 
5 25  OAR25_19926183.1(19270565)(Name=JMJD1C)[ GG GG GG GG GG GG GG GG GG GG GG GG GG GG] 
 OAR25_19941944.1(19286373)(Name=JMJD1C)[ GG GG GG GG GG GG GG GG GG GG GG GG GG GG] 
 OAR25_20026839.1(19369540)(Name=JMJD1C)[ GG GG GG GG GG GG GG GG GG GG GG GG GG GG] 
 OAR25_20041897.1(19386582)(Name=JMJD1C)[ AA AA AA AA AA AA AA AA AA AA AA AA AA AA] 
 OAR25_20106030.1(19438048)(Name=JMJD1C)[ AA AA AA AA AA AA AA AA AA AA AA AA AA AA] 
 
5 13  OAR13_60759835.1(55866953)(Name=CDH26)[ AA AA AA AA AA AA AA AA AA AA AA AA AA AA] 
 s47781.1(55915765)(no gene)[ AA AA AA AA AA AA AA AA AA AA AA AA AA AA] 
 OAR13_60821868.1(55934178)(no gene)[ AA AA AA AA AA AA AA AA AA AA AA AA AA AA] 
 OAR13_60855392.1(55970160)(Name=SYCP2)[ AA AA AA AA AA AA AA AA AA AA AA AA AA AA] 
 OAR13_60893851.1(56010691)(no gene)[ AA AA AA AA AA AA AA AA AA AA AA AA AA AA] 
 
5 11  s44351.1(49904840)(Name=CCDC57)[ AA AA AA AA AA AA AA AA AA AA AA AA AA AA] 
 s30936.1(49940471)(Name=FASN)[ GG GG GG GG GG GG GG GG GG GG GG GG GG GG] 
 s08804.1(49987461)(no gene)[ GG GG GG GG GG GG GG GG GG GG GG GG GG GG] 
 s49850.1(50004896)(no gene)[ AA AA AA AA AA AA AA AA AA AA AA AA AA AA] 




Carrier individuals. 5 minimum sequential homozygous SNPs 
6 14  OAR14_3404872.1(3486435)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 s23868.1(3609268)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OAR14_3688132.1(3712183)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 s10865.1(3782575)(no gene)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00 GA] 
 s57571.1(3800340)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 s30966.1(3813758)(no gene)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00 GA] 
 
6 9  OAR9_75040566.1(70840453)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OAR9_75075388.1(70876514)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR9_75093968.1(70895159)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 s38039.1(70925830)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OAR9_75230004.1(70959064)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00 CC] 
 OAR9_75289690.1(71053054)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 
5 23  OARX_125130516.1(100425156)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OARX_125084587.1(100474082)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OARX_125057668.1(100514641)(no gene)[ 00 00 00 AA 00 00 00 00 AA AA AA 00 00 AA] 
 OARX_125044988.1(100528609)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OARX_125031440.1(100546822)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 
5 18  s40731.1(59640699)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 s10572.1(59668774)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00 AG] 
 OAR18_63721952.1(59706427)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 s36630.1(59743824)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 s50855.1(59799782)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 
5 16  s45053.1(70559566)(Name=AHRR)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OARUn.54_510669.1(70664506)(Name=EXOC3)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 s53565.1(70710282)(Name=SLC9A3)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 s51002.1(70900966)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 s37581.1(70922464)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 
5 14  s66108.1(34390195)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR14_35908377.1(34477621)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
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 s07117.1(34558103)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 s65863.1(34566935)(Name=GFOD2)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00 CC] 
 OAR14_36030253_X.1(34596131)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 
5 13  s67504.1(68158981)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00 AG] 
 s10589.1(68213972)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00 CC] 
 OAR13_73412719.1(68241391)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00 CC] 
 OAR13_73486401.1(68306113)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00 CC] 
 OAR13_73527165.1(68347344)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00 CC] 
 
5 13  s37974.1(15256050)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 s09489.1(15265028)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR13_13397282.1(15307978)(Name=USP6NL)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 s23760.1(15359923)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR13_13298202.1(15406880)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 
5 13  s63569.1(21664236)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR13_24163213.1(21673888)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR13_24206262.1(21688556)(no gene)[ 00 00 CC 00 00 00 00 00 CC CC CC 00 00 CC] 
 s40227.1(21753962)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00 AG] 
 s07619.1(21806857)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 
5 13  OAR13_60759835.1(55866953)(Name=CDH26)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 s47781.1(55915765)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR13_60821868.1(55934178)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR13_60855392.1(55970160)(Name=SYCP2)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR13_60893851.1(56010691)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 
5 11  s35197.1(30193254)(Name=DNAH9)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 s14669.1(30222632)(Name=ZNF18)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR11_32129276.1(30250362)(Name=MAP2K4)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OAR11_32155360.1(30275940)(Name=MAP2K4)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR11_32204952.1(30329562)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 
5 9  s28418.1(80781440)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OAR9_85509697.1(80838913)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
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 OAR9_85560833.1(80885666)(no gene)[ 00 00 CC CC 00 00 00 00 CC CC CC 00 00 CC] 
 OAR9_85594743.1(80924591)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR9_85619253.1(80947471)(no gene)[ 00 00 GA GA 00 00 00 00 GA GA GA 00 00 GA] 
 
5 9  s36433.1(88690261)(Name=CNGB3)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR9_94270944_X.1(88745479)(Name=CPNE3)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR9_94310472.1(88775547)(Name=CPNE3)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 s70574.1(88836294)(Name=WWP1)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OAR9_94375693.1(88900878)(Name=WWP1)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 
5 6  OAR6_28048390.1(24659269)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OAR6_28075131.1(24687510)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR6_28132840.1(24714766)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OAR6_28175615.1(24755360)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR6_28396848.1(24968246)(Name=Uncharacterized)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 
5 3  OAR3_6854899.1(6774118)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OAR3_6897820.1(6820713)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 OAR3_6950846.1(6871259)(no gene)[ 00 00 AA AA 00 00 00 00 AA AA AA 00 00 AA] 
 s58010.1(6884511)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 s13823.1(6989246)(Name=Uncharacterized)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 
5 2  s47673.1(88986269)(no gene)[ 00 00 CC CC 00 00 00 00 CC 00 CC 00 00 CC] 
 s40411.1(88992392)(no gene)[ 00 00 AG AG 00 00 00 00 AG AG AG 00 00 AG] 
 OAR2_95405699.1(89076235)(Name=Uncharacterized)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 
 OAR2_95050543.1(89189237)(no gene)[ 00 00 GG GG 00 00 00 00 GG GG GG 00 00 GG] 




Appendix II: Top 100 SNPs by p-value in PLINK Initial Dataset 
MARKER CHR BP GENENAME GENEBP BPTOGENE A1 A2 MODEL FRQ_AFF FRQ_UN PVAL 
s05374.1 16 22509031 (Close_to)_Name=MAP3K1 22392215..22419948 89083 A G REC 8/0 0/5 0.000312 
OAR10_46125690.1 10 45580754 (Close_to)_Name=KLHL1 44869838..44933847 646907 A G REC 8/1 0/5 0.001281 
OAR1_25842722.1 1 25561238 Name=EPS15 25557772..25839810 
 
G A REC 8/1 0/5 0.001281 
OAR12_83564723.1 12 75920876 Name=Uncharacterized 75883273..75923269 
 
A G REC 8/1 0/5 0.001281 
OAR16_29544100.1 16 27262705 (Close_to)_Name=ISL1 27720710..27730148 458005 G A REC 8/1 0/5 0.001281 
OAR16_29864348.1 16 27555794 (Close_to)_Name=ISL1 27720710..27730148 164916 G A REC 8/1 0/5 0.001281 
OAR23_60556779.1 23 56855903 (Close_to)_Name=ST8SIA3 56832406..56838701 17202 A G REC 8/1 0/5 0.001281 
s67978.1 14 59364622 Name=SHISA7 59341240..59365691 
 
A G REC 8/1 0/5 0.001281 
s70688.1 23 21587590 (Close_to)_Name=Uncharacterized 21463393..21559101 28489 A G REC 8/1 0/5 0.001281 
s71494.1 22 30158667 Name=RBM20 30135041..30358741 
 
G A REC 8/1 0/5 0.001281 
OAR10_42221999.1 10 41420084 (Close_to)_Name=PCDH9 40818672..40821770 598314 A G REC 9/0 1/4 0.001499 
OAR2_195165011.1 2 184070090 Name=PTPN4 184051357..184394205 
 
A G REC 9/0 1/4 0.001499 
OAR3_222203288.1 3 206246224 (Close_to)_Name=FOXJ2 206246262..206314845 38 A G REC 9/0 1/4 0.001499 
s64920.1 2 184492101 Name=RALB 184423271..184497145 
 
G A REC 9/0 1/4 0.001499 
s42749.1 5 106108323 Name=MAN2A1 105985035..106179347 
 
G A REC 7/0 0/3 0.001565 
OAR5_86798856.1 5 79001358 (Close_to)_Name=SSBP2 78722098..78807837 193521 C A REC 7/1 0/5 0.002078 
DU240765_244.1 X 121439986 (Close_to)_Name=RIPPLY1 121429249..121431852 8134 A G REC 5/0 0/4 0.0027 
DU498640_321.1 X 107865244 (Close_to)_Name=OCRL 107805408..107850626 14618 G A REC 5/0 0/4 0.0027 
OARX_27076240.1 X 21770789 Name=PDK3 21723982..21775661 
 
G A REC 5/0 0/4 0.0027 
OAR1_268193141.1 1 248363482 Name=PIK3CB 248349664..248557797 
 
A G REC 0/9 3/1 0.003054 
OAR4_116232256.1 4 108742207 (Close_to)_Name=Uncharacterized 109039190..109039706 296983 A G REC 0/9 3/1 0.003054 
s53402.1 1 263987408 Name=FTCD 263986324..264000997 
 
A G REC 0/9 3/1 0.003054 
s09120.1 17 54115859 Name=PPP1CC 54092664..54203976 
 
A G REC 6/1 0/5 0.003415 
OAR22_4602449.1 22 3698827 (Close_to)_Name=Uncharacterized 3560069..3560720 138107 G A REC 8/1 0/3 0.004678 
OARX_29830880.1 X 22527863 (Close_to)_Name=PPP2R1A 22623303..22625072 95440 G A REC 5/0 0/3 0.004678 
OAR10_16100262.1 10 17223259 (Close_to)_Name=HTR2A 17135647..17196555 26704 G A REC 7/2 0/5 0.005289 
OAR1_135764540.1 1 125198643 Name=TAK1L 125169912..125261167 
 
C A REC 7/2 0/5 0.005289 
OAR1_38581202.1 1 37533058 Name=DOCK7 37492256..37712875 
 
G A REC 7/2 0/5 0.005289 
OAR21_11273092_X.1 21 9756580 (Close_to)_Name=Uncharacterized 9853739..9854363 97159 C A REC 7/2 0/5 0.005289 
OAR21_16900072.1 21 14850333 (Close_to)_Name=Uncharacterized 15153720..15223232 303387 G A REC 7/2 0/5 0.005289 
OAR21_50593433.1 21 45569222 Name=IGHMBP2 45566574..45572457 
 
A C REC 7/2 0/5 0.005289 
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OAR21_50593433.1 21 45569222 Name=MRPL21 45537653..45594155 
 
A C REC 7/2 0/5 0.005289 
OAR2_219701580.1 2 207476786 Name=ADAM23 207429120..207617493 
 
G A REC 7/2 0/5 0.005289 
OAR5_14147739.1 5 11978651 (Close_to)_Name=Uncharacterized 11962085..11962632 16019 G A REC 7/2 0/5 0.005289 
OAR7_95578007.1 7 87876080 Name=NRXN3 87678336..88105158 
 
G A REC 7/2 0/5 0.005289 
s27070.1 10 34319770 (Close_to)_Name=NUPL1 34091325..34247831 71939 A G REC 7/2 0/5 0.005289 
s36676.1 14 58909056 Name=CACNG7 58865906..58932185 
 
A G REC 7/2 0/5 0.005289 
s56510.1 22 16155452 Name=SORBS1 16075857..16209406 
 
A G REC 7/2 0/5 0.005289 
s73257.1 14 59440211 Name=BRSK1 59433357..59452837 
 
G A REC 7/2 0/5 0.005289 
s73257.1 14 59440211 Name=HSPBP1 59422831..59475484 
 
G A REC 7/2 0/5 0.005289 
OAR2_162921437.1 2 153751525 (Close_to)_Name=KCNJ3 153620397..153716544 34981 G A REC 7/2 0/3 0.007215 
OAR25_43581009.1 25 41260077 (Close_to)_Name=GLUD1 41212024..41249846 10231 G A REC 7/0 1/3 0.007215 
OAR3_51396190.1 3 48234418 (Close_to)_Name=CFDP2 48260114..48316549 25696 G A REC 7/1 0/3 0.007215 
s74404.1 20 49767664 (Close_to)_Name=Uncharacterized 49761673..49762401 5263 T A REC 7/1 0/3 0.007215 
s74865.1 22 31081205 (Close_to)_Name=Uncharacterized 31405872..31422997 324667 G A REC 5/0 0/2 0.008151 
OAR10_40339520.1 10 39489315 (Close_to)_Name=PCDH9 39646385..39695585 157070 G A REC 9/0 2/3 0.008752 
OAR10_49726084.1 10 48932289 (Close_to)_Name=KLF12 48967445..49325568 35156 A G REC 9/0 2/3 0.008752 
OAR10_49941391.1 10 49105942 Name=KLF12 48967445..49325568 
 
C A REC 9/0 2/3 0.008752 
OAR10_89499060.1 10 81950954 (Close_to)_Name=Uncharacterized 81839197..81854151 96803 A C REC 0/9 3/2 0.008752 
OAR11_57971056.1 11 54154637 Name=METTL23 54049613..54217476 
 
A G REC 0/9 3/2 0.008752 
OAR11_63539095.1 11 58815143 (Close_to)_Name=Uncharacterized 59402248..59402739 587105 G A REC 0/9 3/2 0.008752 
OAR12_56357383.1 12 50938436 (Close_to)_Name=Uncharacterized 50852326..50853058 85378 G A REC 9/0 2/3 0.008752 
OAR12_65173671.1 12 58752009 (Close_to)_Name=SOAT1 58686926..58751930 79 G A REC 0/9 3/2 0.008752 
OAR1_268175642.1 1 248348219 (Close_to)_Name=PIK3CB 248349664..248557797 1445 A G REC 0/9 3/2 0.008752 
OAR1_275446990.1 1 254866909 (Close_to)_Name=NPHP3 254936877..254990938 69968 A G REC 0/9 3/2 0.008752 
OAR12_82572003.1 12 74953097 Name=C1ORF53 74952060..74953570 
 
A G REC 0/9 3/2 0.008752 
OAR1_287160585.1 1 265450251 (Close_to)_Name=Uncharacterized 265771034..265771240 320783 C A REC 0/9 3/2 0.008752 
OAR14_17682700.1 14 17098867 (Close_to)_Name=Uncharacterized 16993407..17093126 5741 G A REC 0/9 3/2 0.008752 
OAR14_29971688.1 14 28809538 Name=CDH8 28745512..29140552 
 
A G REC 0/9 3/2 0.008752 
OAR15_61453696.1 15 56087018 (Close_to)_Name=RPS3A 56176897..56177691 89879 A G REC 0/9 3/2 0.008752 
OAR1_65172267.1 1 61589657 Name=SYDE2 61571675..61610559 
 
C A REC 0/9 3/2 0.008752 
OAR17_45018430.1 17 41713625 Name=GRIA2 41518585..41716171 
 
A G REC 0/9 3/2 0.008752 
OAR1_77436037.1 1 72378271 (Close_to)_Name=PTBP2 73057054..73115320 678783 A G REC 0/9 3/2 0.008752 
OAR21_13977432.1 21 12314142 (Close_to)_Name=PRCP 12226040..12313295 847 G A REC 0/9 3/2 0.008752 
OAR21_1404105.1 21 1081098 (Close_to)_Name=CCDC67 899477..1027156 53942 G A REC 0/9 3/2 0.008752 
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OAR21_17340576.1 21 15255502 (Close_to)_Name=Uncharacterized 15153720..15223232 32270 G A REC 0/9 3/2 0.008752 
OAR21_36349971.1 21 32729749 (Close_to)_Name=Uncharacterized 32905142..32906130 175393 A G REC 9/0 2/3 0.008752 
OAR21_8713943.1 21 7375018 (Close_to)_Name=BNIP3L 7504274..7504831 129256 A G REC 0/9 3/2 0.008752 
OAR23_27969114_X.1 23 26831850 (Close_to)_Name=Uncharacterized 27076289..27076894 244439 G A REC 0/9 3/2 0.008752 
OAR23_36959489.1 23 34992397 Name=GREB1L 34979403..34995122 
 
G A REC 0/9 3/2 0.008752 
OAR23_58632679.1 23 55141170 Name=TCF4 54803980..55179189 
 
C A REC 0/9 3/2 0.008752 
OAR23_59623047.1 23 55980030 Name=Uncharacterized 55956401..56028668 
 
A G REC 0/9 3/2 0.008752 
OAR3_104479755.1 3 98216780 (Close_to)_Name=Uncharacterized 98044428..98123319 93461 G A REC 0/9 3/2 0.008752 
OAR3_119856323.1 3 112419045 (Close_to)_Name=ZDHHC17 112510300..112590526 91255 G A REC 0/9 3/2 0.008752 
OAR3_123897974.1 3 116215835 Name=PTPRQ 116104058..116578874 
 
G A REC 0/9 3/2 0.008752 
OAR3_124547379.1 3 116846794 (Close_to)_Name=Uncharacterized 116797892..116841830 4964 C A REC 0/9 3/2 0.008752 
OAR3_85112203.1 3 80551030 (Close_to)_Name=PLEKHH2 80437970..80536838 14192 A G REC 0/9 3/2 0.008752 
OAR3_89528817.1 3 84570615 (Close_to)_Name=Uncharacterized 84673885..84681092 103270 G A REC 0/9 3/2 0.008752 
OAR3_99622529.1 3 93811641 (Close_to)_Name=Uncharacterized 94005707..94008560 194066 G A REC 0/9 3/2 0.008752 
OAR4_115857083.1 4 108409074 (Close_to)_Name=Uncharacterized 109039190..109039706 630116 A C REC 0/9 3/2 0.008752 
OAR4_116002501.1 4 108627193 (Close_to)_Name=Uncharacterized 109039190..109039706 411997 G A REC 0/9 3/2 0.008752 
OAR4_116082708.1 4 108574116 (Close_to)_Name=Uncharacterized 109039190..109039706 465074 G A REC 0/9 3/2 0.008752 
OAR6_124646989_X.1 6 109697825 (Close_to)_Name=CPEB2 109725908..109793545 28083 A G REC 9/0 2/3 0.008752 
OAR6_124660937.1 6 109711650 (Close_to)_Name=CPEB2 109725908..109793545 14258 G A REC 9/0 2/3 0.008752 
OAR7_12244180.1 7 11962077 (Close_to)_Name=PARP16 11981614..12005480 19537 A G REC 0/9 3/2 0.008752 
OAR8_40528238.1 8 37619396 (Close_to)_Name=C6ORF168 37512147..37585064 34332 A G REC 0/9 3/2 0.008752 
OAR8_48775633.1 8 45269769 (Close_to)_Name=Uncharacterized 44284182..44306552 963217 A G REC 0/9 3/2 0.008752 
OAR8_50190157.1 8 46706605 (Close_to)_Name=MAP3K7 46809660..46880280 103055 C A REC 9/0 2/3 0.008752 
OAR8_56910466.1 8 53042000 Name=THEMIS 52929118..53133576 
 
A G REC 0/9 3/2 0.008752 
OAR8_58134022.1 8 54236077 Name=LAMA2 54216178..54895696 
 
A G REC 0/9 3/2 0.008752 
OAR8_58181648_X.1 8 54280168 Name=LAMA2 54216178..54895696 
 
A G REC 0/9 3/2 0.008752 
OAR8_75882266.1 8 70709943 (Close_to)_Name=GRM1 70557520..70670365 39578 G A REC 0/9 3/2 0.008752 
OAR8_84067219.1 8 77949827 (Close_to)_Name=RPS6 77948039..77948788 1039 A G REC 0/9 3/2 0.008752 
OAR8_91938724.1 8 85260120 (Close_to)_Name=PACRG 85277553..85380230 17433 C A REC 0/9 3/2 0.008752 
s03652.1 17 41855593 Name=GLRB 41765919..41856956 
 
A G REC 0/9 3/2 0.008752 
s04619.1 23 59008271 (Close_to)_Name=Uncharacterized 59023858..59024268 15587 G A REC 0/9 3/2 0.008752 
s19512.1 3 76037302 (Close_to)_Name=FOXN2 76004936..76026322 10980 G A REC 0/9 3/2 0.008752 
s20069.1 8 79423092 (Close_to)_Name=HADH 79574321..79574761 151229 G A REC 0/9 3/2 0.008752 
s23660.1 8 63246801 Name=NHSL1 63234873..63382699 
 
A G REC 0/9 3/2 0.008752 
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Appendix III: Top 100 SNPs by p-value in PLINK Final Dataset 
MARKER CHR BP GENENAME GENEBP BPTOGENE A1 A2 MODEL FRQ_AFF FRQ_UN PVAL 
OAR12_83564723.1 12 75920876 Name=Uncharacterized 75883273..75923269 A G REC 12/2 0/6 0.000336 
OAR23_60556779.1 23 56855903 (Close_to)_Name=ST8SIA3 56832406..56838701 17202 A G REC 12/2 0/6 0.000336 
OAR5_14147739.1 5 11978651 (Close_to)_Name=Uncharacterized 11962085..11962632 16019 G A REC 12/2 0/6 0.000336 
OAR25_43581009.1 25 41260077 (Close_to)_Name=GLUD1 41212024..41249846 10231 G A REC 12/0 41365 0.000395 
s05374.1 16 22509031 (Close_to)_Name=MAP3K1 22392215..22419948 89083 A G REC 11/2 0/6 0.000516 
OAR10_49726084.1 10 48932289 (Close_to)_Name=KLF12 48967445..49325568 35156 A G REC 14/0 2/4 0.000636 
OAR21_36349971.1 21 32729749 (Close_to)_Name=Uncharacterized 32905142..32906130 175393 A G REC 14/0 2/4 0.000636 
OAR2_195165011.1 2 1.84E+08 Name=PTPN4 184051357..184394205 A G REC 14/0 2/4 0.000636 
OAR6_124646989_X.1 6 1.1E+08 (Close_to)_Name=CPEB2 109725908..109793545 28083 A G REC 14/0 2/4 0.000636 
OAR6_124660937.1 6 1.1E+08 (Close_to)_Name=CPEB2 109725908..109793545 14258 G A REC 14/0 2/4 0.000636 
DU498640_321.1 23 1.08E+08 (Close_to)_Name=SERPINB10 62299681..62326225 45539019 G A REC 13/1 1/5 0.000656 
OAR10_42221999.1 10 41420084 (Close_to)_Name=PCDH9 40818672..40821770 598314 A G REC 13/1 1/5 0.000656 
OARX_27076240.1 23 21770789 (Close_to)_Name=GALNT1 21679987..21748387 22402 G A REC 13/1 1/5 0.000656 
OAR10_16100262.1 10 17223259 (Close_to)_Name=HTR2A 17135647..17196555 26704 G A REC 11/3 0/6 0.001209 
OAR21_11273092_X.1 21 9756580 (Close_to)_Name=Uncharacterized 9853739..9854363 97159 C A REC 11/3 0/6 0.001209 
OAR21_16900072.1 21 14850333 (Close_to)_Name=Uncharacterized 15153720..15223232 303387 G A REC 11/3 0/6 0.001209 
OAR24_37064565.1 24 33961710 (Close_to)_Name=CCL26 33952957..33957507 4203 G A REC 11/3 0/6 0.001209 
OARX_29188769.1 23 19623665 Name=Uncharacterized 19583942..19640640 G A REC 11/3 0/6 0.001209 
s27070.1 10 34319770 (Close_to)_Name=NUPL1 34091325..34247831 71939 A G REC 11/3 0/6 0.001209 
s43015.1 24 33953578 Name=CCL26 33952957..33957507 G A REC 11/3 0/6 0.001209 
OAR3_193744872.1 3 1.8E+08 Name=IFT27 179967963..179990644 G A REC 10/3 0/6 0.001799 
s10237.1 24 24989534 Name=IL21R 24987787..25002160 A C REC 10/3 0/6 0.001799 
s09120.1 17 54115859 Name=PPP1CC 54092664..54203976 A G REC 10/1 1/5 0.002205 
OAR26_14049024.1 26 11375662 (Close_to)_Name=ODZ3 12081624..12141082 705962 C A REC 11/3 0/5 0.002254 
OAR5_10935525.1 5 9535742 (Close_to)_Name=CD97 9450503..9467533 68209 A G REC 11/3 0/5 0.002254 
OAR10_25624621.1 10 25709520 (Close_to)_Name=Uncharacterized 25678169..25678828 30692 A G REC 12/2 1/5 0.00301 
OAR10_33307197.1 10 33021724 Name=Uncharacterized 32941724..33027426 G A REC 12/2 1/5 0.00301 
OAR10_33338187.1 10 33053891 (Close_to)_Name=Uncharacterized 32941724..33027426 26465 G A REC 12/2 1/5 0.00301 
OAR10_58058749.1 10 56914955 (Close_to)_Name=NFYB 56251109..56270332 644623 A G REC 12/2 1/5 0.00301 
OAR10_69032148.1 10 66779341 Name=GPC5 66542081..66793149 G A REC 12/2 1/5 0.00301 
OAR1_25842722.1 1 25561238 Name=EPS15 25557772..25839810 G A REC 12/2 1/5 0.00301 
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s06239.1 24 9352754 (Close_to)_Name=TEKT5 9359214..9407395 6460 A G REC 12/2 1/5 0.00301 
s43183.1 10 51411639 (Close_to)_Name=LMO7 51117948..51358374 53265 A G REC 12/2 1/5 0.00301 
s51842.1 25 41186480 (Close_to)_Name=SNCG 41170873..41183542 2938 G A REC 12/2 1/5 0.00301 
s67978.1 14 59364622 Name=SHISA7 59341240..59365691 A G REC 12/2 1/5 0.00301 
OAR10_29907137.1 10 29882404 (Close_to)_Name=B3GALTL 29893792..29994174 11388 A G REC 11/1 1/4 0.003128 
OAR10_25988324.1 10 26056792 Name=NBEA 26011868..26592547 A G REC 10/4 0/6 0.003415 
OAR12_10816504.1 12 8708988 (Close_to)_Name=Uncharacterized 8511596..8512941 196047 A G REC 10/4 0/6 0.003415 
OAR16_31129400.1 16 28754634 (Close_to)_Name=EMB 28692740..28753002 1632 A G REC 10/4 0/6 0.003415 
OAR21_10442989.1 21 9036537 (Close_to)_Name=PICALM 8950524..9036200 337 A G REC 10/4 0/6 0.003415 
OAR21_10461107.1 21 9054725 (Close_to)_Name=PICALM 8950524..9036200 18525 C A REC 10/4 0/6 0.003415 
OAR24_30139569_X.1 24 27613295 Name=MRPS17 27612710..27636615 G A REC 10/4 0/6 0.003415 
OAR24_30146533.1 24 27620251 Name=MRPS17 27612710..27636615 A G REC 10/4 0/6 0.003415 
OAR3_182795446.1 3 1.7E+08 (Close_to)_Name=UTP20 170228696..170315908 29193 A C REC 10/4 0/6 0.003415 
OAR3_19616550_X.1 3 18106309 Name=KIDINS220 18105955..18190292 A G REC 10/4 0/6 0.003415 
OAR3_25097037.1 3 23336791 (Close_to)_Name=NBAS 23499495..23835462 162704 C A REC 10/4 0/6 0.003415 
s14379.1 3 1.8E+08 (Close_to)_Name=IFT27 179967963..179990644 1554 G A REC 10/4 0/6 0.003415 
s27590.1 1 2.64E+08 (Close_to)_Name=S100B 264414341..264417467 9247 G A REC 10/4 0/6 0.003415 
s56268.1 10 25943893 (Close_to)_Name=Uncharacterized 25954017..25970895 10124 G A REC 10/4 0/6 0.003415 
s60222.1 23 45564934 (Close_to)_Name=SLC14A2 45567420..45633026 2486 G A REC 10/4 0/6 0.003415 
s60732.1 1 2.68E+08 (Close_to)_Name=Uncharacterized 268094342..268197646 38051 G A REC 10/4 0/6 0.003415 
s61799.1 10 30924195 (Close_to)_Name=UBL3 31052832..31095668 128637 G A REC 10/4 0/6 0.003415 
s70688.1 23 21587590 (Close_to)_Name=Uncharacterized 21463393..21559101 28489 A G REC 10/4 0/6 0.003415 
s71494.1 22 30158667 Name=RBM20 30135041..30358741 G A REC 10/4 0/6 0.003415 
OAR14_68222343.1 14 61709350 (Close_to)_Name=Uncharacterized 61693493..61697083 12267 A C REC 8/3 0/6 0.004092 
OAR10_5693105.1 10 7492074 (Close_to)_Name=PCDH17 5438145..5545654 1946420 C A REC 0/14 3/3 0.004108 
OAR10_87392185.1 10 80078689 (Close_to)_Name=Uncharacterized 79988268..79991729 86960 A C REC 0/14 3/3 0.004108 
OAR15_61453696.1 15 56087018 (Close_to)_Name=RPS3A 56176897..56177691 89879 A G REC 0/14 3/3 0.004108 
OAR15_72854094.1 15 67326393 (Close_to)_Name=Uncharacterized 68406735..68410135 1080342 A G REC 0/14 3/3 0.004108 
OAR16_29788902.1 16 27479191 (Close_to)_Name=ISL1 27720710..27730148 241519 G A REC 0/14 3/3 0.004108 
OAR16_32987078.1 16 30357140 (Close_to)_Name=FGF10 30468800..30562188 111660 G A REC 0/14 3/3 0.004108 
OAR16_63260453_X.1 16 57955217 (Close_to)_Name=ANKH 58190075..58357213 234858 G A REC 0/14 3/3 0.004108 
OAR16_71436671.1 16 65681259 Name=ADCY2 65280195..65721159 A C REC 0/14 3/3 0.004108 
OAR17_45018430.1 17 41713625 Name=GRIA2 41518585..41716171 A G REC 0/14 3/3 0.004108 
OAR17_75701731.1 17 69462601 Name=INPP5J 69374736..69488557 A C REC 0/14 3/3 0.004108 
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OAR18_16433946.1 18 16365432 Name=AGBL1 16105736..16817080 G A REC 0/14 3/3 0.004108 
OAR23_36959489.1 23 34992397 Name=GREB1L 34979403..34995122 G A REC 0/14 3/3 0.004108 
OAR3_35192406.1 3 32861548 Name=DTNB 32602005..32903617 G A REC 0/14 3/3 0.004108 
OAR4_26645098.1 4 25358759 Name=TSPAN13 25327414..25364818 A G REC 0/14 3/3 0.004108 
OAR6_123771724.1 6 1.09E+08 (Close_to)_Name=Uncharacterized 109032515..109032766 160073 A G REC 0/14 3/3 0.004108 
OAR6_126093150.1 6 1.11E+08 (Close_to)_Name=Uncharacterized 110908934..110910259 119185 G A REC 0/14 3/3 0.004108 
OAR8_40528238.1 8 37619396 (Close_to)_Name=C6ORF168 37512147..37585064 34332 A G REC 0/14 3/3 0.004108 
OAR8_47582140.1 8 44115521 (Close_to)_Name=EPHA7 44013118..44048755 66766 A C REC 0/14 3/3 0.004108 
OAR8_48775633.1 8 45269769 (Close_to)_Name=Uncharacterized 44284182..44306552 963217 A G REC 0/14 3/3 0.004108 
OAR8_50190157.1 8 46706605 (Close_to)_Name=MAP3K7 46809660..46880280 103055 C A REC 14/0 3/3 0.004108 
OAR8_84067219.1 8 77949827 (Close_to)_Name=RPS6 77948039..77948788 1039 A G REC 0/14 3/3 0.004108 
s03652.1 17 41855593 Name=GLRB 41765919..41856956 A G REC 0/14 3/3 0.004108 
s10803.1 6 1.1E+08 (Close_to)_Name=Uncharacterized 109516618..109616046 10377 A G REC 0/14 3/3 0.004108 
s57209.1 6 1.11E+08 Name=LDB2 111166384..111261472 C A REC 0/14 3/3 0.004108 
s65924.1 16 17453973 (Close_to)_Name=Uncharacterized 17095578..17096622 357351 A G REC 0/14 3/3 0.004108 
s67019.1 9 94116528 Name=COL14A1 93985570..94217441 A G REC 0/14 3/3 0.004108 
s60527.1 3 30648203 (Close_to)_Name=Uncharacterized 30552647..30582515 65688 A C REC 11/2 1/5 0.004316 
s67652.1 24 3439178 Name=SRL 3423050..3457451 A G REC 11/2 1/5 0.004316 
OAR10_40339520.1 10 39489315 (Close_to)_Name=PCDH9 39646385..39695585 157070 G A REC 13/1 2/4 0.004845 
OAR10_49941391.1 10 49105942 Name=KLF12 48967445..49325568 C A REC 13/1 2/4 0.004845 
OAR10_50744611.1 10 49914859 (Close_to)_Name=N4BP2 49655604..49656128 258731 G A REC 13/1 2/4 0.004845 
OAR10_60925663.1 10 59463069 (Close_to)_Name=SLITRK1 59237084..59242396 220673 A C REC 13/1 2/4 0.004845 
OAR10_71498684.1 10 69161897 (Close_to)_Name=GPC6 69280455..69417471 118558 G A REC 13/1 2/4 0.004845 
OAR11_14058741.1 11 14184155 Name=TAF15 14145853..14215694 A G REC 13/1 2/4 0.004845 
OAR11_14058741.1 11 14184155 Name=MMP28 14174664..14212927 A G REC 13/1 2/4 0.004845 
OAR1_265795032.1 1 2.46E+08 (Close_to)_Name=RPS19 246180197..246180640 43573 G A REC 13/1 2/4 0.004845 
OAR1_77436037.1 1 72378271 (Close_to)_Name=PTBP2 73057054..73115320 678783 A G REC 1/13 4/2 0.004845 
OAR2_194104000.1 2 1.83E+08 (Close_to)_Name=Uncharacterized 183101112..183110042 40730 C A REC 13/1 2/4 0.004845 
OAR23_59623047.1 23 55980030 Name=Uncharacterized 55956401..56028668 A G REC 1/13 4/2 0.004845 
OAR3_104479755.1 3 98216780 (Close_to)_Name=Uncharacterized 98044428..98123319 93461 G A REC 1/13 4/2 0.004845 
OAR3_119856323.1 3 1.12E+08 (Close_to)_Name=ZDHHC17 112510300..112590526 91255 G A REC 1/13 4/2 0.004845 
OAR3_123897974.1 3 1.16E+08 Name=PTPRQ 116104058..116578874 G A REC 1/13 4/2 0.004845 
OAR3_124547379.1 3 1.17E+08 (Close_to)_Name=Uncharacterized 116797892..116841830 4964 C A REC 1/13 4/2 0.004845 
OAR3_99622529.1 3 93811641 (Close_to)_Name=Uncharacterized 94005707..94008560 194066 G A REC 1/13 4/2 0.004845 
Appendices 18 
 





Appendix V: Perl source code for Homozygosity_Mapper 
Please note that font size has been decreased to assist with layout readability of the code 
#!/usr/bin/perl 
 
# Authors: Jez Supreme and Kim Carter, 2013 
# Purpose: Script to identify runs of homozygous SNP markers from linkage formatted data 
#  
# Inputs:  1. .ped text fle, in standard linkage ped format 
#    2. .map text file, in standard linkage map format 
#          3. .dat text file, in standard linkage dat format 
#          4. affection status to filter in ped file ie 2=only affecteds, 1=only carriers/controls 
#    5. number of mismatches (genotypes) allowed within a run of HZ  
#    6. cutoff filter to reduce outputs ie minimum length of HZ runs of SNPs to display 
 





#locate of sheep genome annotation file 
my $gff = "/data/gff_files/Oarv3.1.protein.gene.gff3"; 
 
#check correct arguments are supplied 
if ($#ARGV!=5) { 





my $mapfilecol = 3; # ie 4 colum map 
my $pedfile = $ARGV[0]; 
my $mapfile = $ARGV[1]; 
my $datfile = $ARGV[2]; 
my $aff = $ARGV[3]; 
my $mismatch = $ARGV[4]; 
my $cutoff = $ARGV[5]; 
my %results = (); 
my %start = (); 
my %end = (); 
my %names = (); 
 
#read GFF file into memory 
open(GFF, "<$gff") || die("Failed to open $gff for reading"); 
while(<GFF>) 
{ 
 my $line = $_; 
 chomp($line); 
 
 $line =~ s/\n//g;  # \n 
 $line =~ s/\r//g;  # \r 
         
 my @cols = split(/\t/,$line); # split it 
 
 if ($cols[2] eq "mRNA") # only save features if they are MRNA ie gene features 
 { 
  #scaffold004293 GLEAN mRNA 16 1497 0.999942 - .      
 D=CCG000001.0;Name=Uncharacterized;Homology=B4AF47_BACPU;Note=BLAST.hit.in.refproteindatabaseB4AF47 
 
  #extract name and chromsome from annotation   
  my $namebit = $cols[8]; 
  my @ns = split(/;/,$namebit); # split it 
   
  my $chr = $cols[0]; 
  #OAR11 
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  if ($chr =~ m/OAR/) 
  { 
   $chr = substr($chr,3); 
  } 
    
 
  #save gene start and end positions 
  if (exists($start{$chr}{$cols[3]})) 
  { 
   $start{$chr}{$cols[3]} = $start{$chr}{$cols[3]}."::".$ns[1]; 
 
  } 
  else 
  { 
   $start{$chr}{$cols[3]} = $ns[0]; 
    
  } 
 
  $end{$chr}{$ns[0]} = $cols[4]; 
 
  #print "Saving: $chr, $cols[3]..$cols[4] as $ns[0]\n"; 






#read DAT file into memory 
my %datmap = (); 
my $mcount=-1; 




 my $line = $_; 
 chomp($line); 
 
 #trim end of line characters 
 $line =~ s/\n//g;  # \n 
 $line =~ s/\r//g;  # \r 
        $line =~ s/\t/ /g; 
 $line =~ s/^\s+//; 
 $line =~ s/\s+$//; 
  
 if ($line =~/^M /) 
 { 
  $mcount++; 
   
  #save marker 
  # (6 + (mnumber*2)) and (6 + (mcount*2)+1) 
  my @cols = split(/ /,$line); # split it 
  
  # datmap{colun number in ped file} -> snp name 
  $datmap{(6+($mcount*2))} = $cols[1];  #get name for column 






#read map file into memory 
my %markerinfo = (); 
open(COLS, "<$mapfile") || die("Failed to open $mapfile for reading"); 
while(<COLS>) 
{ 
 my $line = $_; 
 chomp($line); 
 
 #trim end of line characters 
 $line =~ s/\n//g;  # \n 
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 $line =~ s/\r//g;  # \r 
        $line =~ s/\t/ /g; 
 $line =~ s/^\s+//; 
 $line =~ s/\s+$//; 
 
 #save marker location - chromosome and position 
 my @cols = split(/ /,$line); # split it 
 $markerinfo{$cols[1]}{CHR} = $cols[0]; 







#read ped file into memory 





 my $line = $_;  
 chomp($line); 
 $line =~ s/\n//g;  # \n 
 $line =~ s/\r//g;  # \r 
 $line =~ s/\t/ /g; 
 
 #split col list 
 my @cols = split(/ /,$line); # split it 
 
 if ($cols[5] == $aff)  # lets just look in affecteds/controls 
 { 
  $scount++; 
  for(my $i=6; $i<=$#cols; $i=$i+2) 
  { 
   $sheep{$cols[1]}{$i} = $cols[$i].$cols[$i+1]; 




print "Finished reading ped - examining HZ in $scount individuals\n"; 
 
 
#now sort through data, one SNP at a time, looking for runs of 1 or more 
#SNPs that are all HZ (or with wobble mismatch included) 
 
#declare newvariables for this part 
my @ids = sort {$a cmp $b} keys %sheep; 








foreach my $m (@markers) #check for all markers 
{ 
 
 my $name = $datmap{$m}; 
 if (!exists($datmap{$m})) 
 { 





 #get details of this marker 
 my $p = $markerinfo{$name}{"POS"}; 





 #check if on same chrom. If no, then check if we are in a run of HZ or not 
 if ($oldc ne $c) 
 { 
  if ($hz>0) 
  { 
   if ($hz>=$cutoff) #if hit end of chrom, and found a region of HZ, then save it 
 
    #must be the old chrom saved 
    $results{$hz}{$oldc}{$hzstring}=1; 
 
   } 
    
   $hz=0; 
   $hzstring=""; 






 #Get the genotypes for the sheep, seeing if HZ (get the first one listed in the ped file) 
 my $fail1=0; 
 my $a1 = ""; 
 for (my $i=0; $i<=$#ids; $i++) 
 { 
  if ($sheep{$ids[$i]}{$m} ne "00" && $sheep{$ids[$i]}{$m} ne "") 
  { 
   $a1 = $sheep{$ids[$i]}{$m}; 
   $i=$#ids+1; 
    
  } 
 } 
  
 my $genostring="["; 
 
 #now complete with the rest, checking if the genotypes are HZ with the first 
 for (my $i=0; $i<=$#ids; $i++) 
 { 
  $genostring = $genostring." $sheep{$ids[$i]}{$m}"; 
   
   
  if ($sheep{$ids[$i]}{$m} ne $a1 && $sheep{$ids[$i]}{$m} ne "00" && $sheep{$ids[$i]}{$m} ne "") 
  { 
   $fail1++; 
  } 
 } 
 
 $genostring = $genostring."]"; 
 
 #if the number of 'failed' matches is less than our threshold, then save this HZ region 
 if ($fail1<=$mismatch &&  $a1 && $a1 ne "00" && $a1 ne "" && $a1 ne " ") 
 { 
 
  #if saving, then lookup GFF details 
  my @ks = sort {$start{$c}{$a} cmp $start{$c}{$b}} keys %{$start{$c}}; 
 
  my $found=0; 
  my $genename="(no gene)"; 
  foreach my $k (@ks) 
  { 
   #print "Checking if $cols[3] >= $k and $cols[3] <= $end{$chr}{$start{$chr}{$k}} \n"; 
 
   if ($p >= $k && $p <= $end{$c}{$start{$c}{$k}}) 
   { 
    $found++; 
    $genename="($names{$c}{$k}{$end{$c}{$start{$c}{$k}}})"; 
   } 




    
  $hz++; 





  # this SNP failed our threshold test, but we need to check if this is the end of a run of HZ 
  if ($hz>0) 
  { 
   if ($hz>=$cutoff) 
   { 
 
    #save old chrom   
    $results{$hz}{$oldc}{$hzstring}=1; 
   
   } 
    
   $hz=0; 
   $hzstring=""; 







 if ($m==$#markers) 
 { 
  if ($hz>=$cutoff) 
  { 
   #save old chrom   
   $results{$hz}{$oldc}{$hzstring}=1; 
   
  } 
 } 
 
 #save old chrom 







# Now print all the saved regions, sorted from longest to shortest 
print "Top results with <= $mismatch per genotype, reporting runs >= $cutoff\n\n"; 
print "HZcount\tCHROM\tMARKERS\n"; 
 
my @hzs = sort {$b<=>$a} keys %results; 
foreach my $h (@hzs) 
{ 
 my @chrs = sort {$b<=>$a} keys %{$results{$h}}; 
 foreach my $c (@chrs) 
 {  
  my @annots = sort {$b<=>$a} keys %{$results{$h}{$c}}; 
  foreach my $a (@annots) 
  {  
   print "$h\t$c\t$a\n"; 








Appendix VI: perl source code for Haplotype_Extractor 
Please note that font size has been decreased to assist with layout readability of the code 
#!/usr/bin/perl 
 
# Authors: Jez Supreme and Kim Carter, 2013 
# Purpose: Script to extract a subset of markers from a set of pedigree files 
#  
# Inputs:  1. .dat text file, in standard linkage dat format 
#          2. target markers (to extract), one marker per line 
#          3. .ped text fle, in standard linkage ped format 
 




#check correct arguments are supplied) 
if ($#ARGV!=3) { 






my $datfile = $ARGV[0];   ##full list of SNPs 
my $exfile = $ARGV[1];   ##which SNPs targeted 
my $pedfile = $ARGV[2];  ##pedigree file 
my $newped = $ARGV[3];  ##output haplotype 
 
my %map = (); 
 
##### ASSUMPTION #################### 
 
#ped file =  
# 
#   col 0 = FID 
#       1 = IID 
#       2 = FAID 
#       3 = MOID 
#       4 = SEX 
#       5 = AFF 
#       6 = SNP MARKER ALLELE 1 
#       (and rest of SNP alleles) 
 
 
#read DAT file into memory 




 my $line = $_; 
 chomp($line); 
 $line =~ s/\n//g;  # \n 
 $line =~ s/\r//g;  # \r 




 if ($line =~ m/^M/)  #markers only, ie skip A Affection 
 { 
  my @cols = split(/ /,$line); # split it 
  $map{$pos} = $cols[1]; 
  $pos = $pos+2; 
 } 
 elsif ($line =~ m/^A/)  #markers only, ie skip A Affection 
        { 
                my @cols = split(/ /,$line); # split it 
                $map{5} = $cols[1]; 





#read extract markers file, one per line 
my %toremove = (); 
open(IN, "<$exfile") || die("Failed to open $exfile for reading"); 
while(<IN>) 
{ 
 my $line = $_; 
 chomp($line); 
 $line =~ s/\n//g;  # \n 
 $line =~ s/\r//g;  # \r 
        $line =~ s/\t/ /g; 
  
 $toremove{$line} = 1; 





#read PED file, into memory, and extract only the subset of markers requested -> printing the new ped file 
open(IN, "<$pedfile") || die("Failed to open $pedfile for reading"); 
open(OUT, ">$newped") || die("Failed to open $newped for writing"); 
open(OUTDAT, ">$newped.dat") || die("Failed to open $newped.dat for writing"); 
while(<IN>) 
{ 
 my $line = $_; 
 chomp($line); 
 $line =~ s/\n//g;  # \n 
 $line =~ s/\r//g;  # \r 
        $line =~ s/\t/ /g; 
 
 my @cols = split(/ /,$line); # split it 
 print OUT "$cols[0] $cols[1] $cols[2] $cols[3] $cols[4] $cols[5]"; 
 for(my $i=6; $i<=$#cols; $i=$i+2) 
 { 
  if (exists($toremove{$map{$i}})) 
  { 
   print OUT " ".$cols[$i]." ".$cols[$i+1];      
     
  } 
  else 
  { 
    
  } 
  
 } 







#print the new DAT file 
my @keys = sort {$a<=>$b} keys %map; 
foreach my $k (@keys) 
{ 
 if ($k==5) 
 { 




  if (exists($toremove{$map{$k}})) 
                { 
    #write to dat file 
   print OUTDAT "M ".$map{$k}."\n"; 






print "\nNew haplotype written to $newped\n"; 





Appendix VII: perl source code for the Plink_Parser 
Please note that font size has been decreased to assist with layout readability of the code 
#!/usr/bin/perl 
 
# Authors: Jez Supreme and Kim Carter, 2013 
# Purpose: Script to rear in Plink.model association outputs, and merge in nearest genes using genome locations from a GFF file 
#  
# Inputs:  1. Plink model file to parse 
#          2. Formatted .map file in standard linkage map format (used to locate a marker) 
#          3. Significant cutoff - maximum value to filter association p-values by, eg 0.05 
#    4. Association model -  REC, GENO, DOM, TREND, ALLELIC 
 
# Outputs:  Summary of plink model association, with nearest gene in a column separated format 




#GFF file location - Sheep genome version 3.1 
my $gff = "/data/gff_files/Oarv3.1.protein.gene.gff3"; 
my $mapcols = 3;  #number of the basepair column in a linkage map file  
 
#check required inputs are provided 
if ($#ARGV!=3) { 






my $sig = $ARGV[2]; 
my $model = $ARGV[3]; 
my %start = (); 
my %end = (); 
my %names = (); 
 
 
#open GFF file, and read into memory 
open(GFF, "<$gff") || die("Failed to open $gff for reading"); 
while(<GFF>) 
{ 
 #trim newline character 
 my $line = $_; 
 chomp($line); 
 
 $line =~ s/\n//g;  # \n 
 $line =~ s/\r//g;  # \r 
         
 my @cols = split(/\t/,$line); # split it 
 
 if ($cols[2] eq "mRNA") # grab only MRNA (ie gene) features 
 { 
  #scaffold004293 GLEAN mRNA 16 1497 0.999942 - .  
 D=CCG000001.0;Name=Uncharacterized;Homology=B4AF47_BACPU;Note=BLAST.hit.in.refproteindatabaseB4AF47 
   
  #parse the name 
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  my $namebit = $cols[8]; 
  my @ns = split(/;/,$namebit); # split it 
  #print "@ns\n"; 
 
  #parse the chromosome   
  my $chr = $cols[0]; 
  #OAR11 
  if ($chr =~ m/OAR/) 
  { 
   $chr = substr($chr,3); 
  } 
    
 
  #store the start and end positions in hash tables 
  if (exists($start{$chr}{$cols[3]})) 
  { 
    
   #print "dupe\n"; 
   $start{$chr}{$cols[3]} = $start{$chr}{$cols[3]}."::".$ns[1]; 
  } 
  else 
  { 
   $start{$chr}{$cols[3]} = $ns[0]; 
  } 
  $end{$chr}{$ns[0]} = $cols[4]; 
 




#print "Finished reading GFF\n"; 
 
 
# Read the plink.model into memory 
my %markers = (); 
open(PLINK, "<$ARGV[0]") || die("Failed to open $ARGV[0] for reading"); 
while(<PLINK>) 
{ 
 #CHR                           SNP   A1   A2     TEST            AFF          UNAFF        C 
#HISQ   DF            P 
 
 my $line = $_; 
 chomp($line); 
 
 #trim end of line characters and multiple whitespaces 
 $line =~ s/\n//g;  # \n 
 $line =~ s/\r//g;  # \r 
        $line =~ s/\t/ /g; 
 $line =~ s/\h+/ /g; 
 
 $line =~ s/^\s+//; 
 $line =~ s/\s+$//; 
  




  my @cols = split(/ /,$line); # split i         
  #print "$cols[1]::$cols[4]::$cols[9]\n"; 
 
  #save this SNP result if its the correct model, and meets the significance cutoff 
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  if ($cols[4] eq $model && $cols[9] ne "NA" && $cols[9] <= $sig) 
  { 
   $markers{$cols[1]} = $line; 
   #print "Storing marker $cols[1]: $line\n"; 
  








#open the map file and check where our significnant markers are, relative to the GFF features 
print "MARKER\tCHROM\tBP\tGENEID\tGENENAME\tGENEBP\tDISTANCETOGENE\tA1\tA2\tMODEL\tFRQ_AFF\tFRQ_UNAFF\tPVAL\n"; 




 my $line = $_; 
 chomp($line); 
 
 #trim end of line 
 $line =~ s/\n//g;  # \n 
 $line =~ s/\r//g;  # \r 
        $line =~ s/\t/ /g; 
 $line =~ s/^\s+//; 
 $line =~ s/\s+$//; 
 
 
 my @cols = split(/ /,$line); # split it 
 my $chr = $cols[0]; 
 if ($chr =~ m/^OAR/) 
 { 
  $chr = substring($chr,3); 
 } 
 
 #found the marker in the significant list 
 if (exists($markers{$cols[1]})) 
 { 
  #print "here\n"; 
  
  my @ms = split(/ /,$markers{$cols[1]}); 
 
 
  my @ks = sort {$start{$chr}{$a} cmp $start{$chr}{$b}} keys %{$start{$chr}};  ##NEW 
 
  #check if the SNP falls within a gene 
  my $found=0; 
  foreach my $k (@ks) 
  { 
   #print "Checking if $cols[3] >= $k and $cols[3] <= $end{$chr}{$start{$chr}{$k}} \n"; 
 
   if ($cols[$mapcols] >= $k && $cols[$mapcols] <= $end{$chr}{$start{$chr}{$k}}) 
   { 
    print 
"$cols[1]\t$chr\t$cols[$mapcols]\t$start{$chr}{$k}\t$names{$chr}{$k}{$end{$chr}{$start{$chr}{$k}}}\t$k..$end{$chr}{$start{$chr}{$k}}\t\t$ms[2]\t$ms[3]\t$ms[4]\t$ms[5]\t$ms[6]\t$ms[9]\n"; 
    $found++; 
 
   } 




  #if a SNP doesn't fall within a gene, find the nearest upstream or downstream 
  if ($found==0) 
  { 
   #print "No gene found for $line\n"; 
   
   my $close = 999999999; 
   my $close_gene = "\t\t\t\t\t\t\t\t\t\n"; 
   
   my @starts = sort {$start{chr}{$a} cmp $start{$chr}{$b}} keys %{$start{$chr}}; 
   foreach my $s (@starts) 
   { 
    if ($s-$cols[$mapcols] <= $close && $s-$cols[$mapcols]>=0) 
    { 
     $close = $s-$cols[$mapcols]; 
     $close_gene = 
"(Close_to)_".$start{$chr}{$s}."\t(Close_to)_".$names{$chr}{$s}{$end{$chr}{$start{$chr}{$s}}}."\t$s..$end{$chr}{$start{$chr}{$s}}\t$close\t$ms[2]\t$ms[3]\t$ms[4]\t$ms[5]\t$ms[6]\t$ms[9]\n"; 
    } 
 
    if ($cols[$mapcols]-$end{$chr}{$start{$chr}{$s}} <= $close && $cols[$mapcols]-$end{$chr}{$start{$chr}{$s}}>=0) 
    { 
     $close = $cols[$mapcols]-$end{$chr}{$start{$chr}{$s}}; 
     $close_gene = 
"(Close_to)_".$start{$chr}{$s}."\t(Close_to)_".$names{$chr}{$s}{$end{$chr}{$start{$chr}{$s}}}."\t$s..$end{$chr}{$start{$chr}{$s}}\t$close\t$ms[2]\t$ms[3]\t$ms[4]\t$ms[5]\t$ms[6]\t$ms[9]\n"; 
    } 
 
 
   }   
    
   print "$cols[1]\t$chr\t$cols[$mapcols]\t$close_gene"; 
 
   





  #die "Marker $cols[1] not found in GFF\n"; 
 } 
 
} 
close(MAP); 
 
 
 
 
